JP World Journal of W Psychiatry

Submit a Manuscript: https://www.f6publishing.com

World J Psychiatry 2022 May 19; 12(5): 739-765

DOI: 10.5498/wjp.v12.i5.739

ISSN 2220-3206 (online)

META-ANALYSIS

# Mental health impact of the Middle East respiratory syndrome, SARS, and COVID-19: A comparative systematic review and metaanalysis

Gayathri Delanerolle, Yutian Zeng, Jian-Qing Shi, Xuzhi Yeng, Will Goodison, Ashish Shetty, Suchith Shetty, Nyla Haque, Kathryn Elliot, Sandali Ranaweera, Rema Ramakrishnan, Vanessa Raymont, Shanaya Rathod, Peter Phiri

Specialty type: Psychiatry	<b>Gayathri Delanerolle</b> , Nuffield Department of Primary Health Care Science, University of Oxford, Oxford OX2 6ED, United Kingdom			
<b>Provenance and peer review:</b> Invited article; Externally peer reviewed.	Yutian Zeng, Jian-Qing Shi, Xuzhi Yeng, Southern University of Science and Technology, Shenzhen 518055, Guangdong Province, China			
Peer-review model: Single blind	Jian-Qing Shi, The Alan Turing Institute, London NW1 2DB, United Kingdom			
Peer-review report's scientific quality classification	Will Goodison, Ashish Shetty, University College London Hospital NHS Foundation Trust, London NW1 2PG, United Kingdom			
Grade A (Excellent): A, A, A Grade B (Very good): 0	Ashish Shetty, University College London, London WC1E 6BT, United Kingdom			
Grade C (Good): C Grade D (Fair): 0	Suchith Shetty, Kathryn Elliot, Shanaya Rathod, Peter Phiri, Department of Research and Innovation, Southern Health NHS Foundation Trust, Southampton SO30 3JB, United Kingdom			
Grade E (Poor): 0 <b>P-Reviewer:</b> Lu C, China; Sageena	Nyla Haque, Vanessa Raymont, Department of Psychiatry, University of Oxford, Oxford OX2 6ED, United Kingdom			
G, India; Wang MZ, China; Yu L, Singapore	Sandali Ranaweera, Department of BioSystems Technology, University of Sri Jayewardenepura, Nugegoda 10100, Sri Lanka			
Received: October 28, 2021 Peer-review started: October 28, 2021	Rema Ramakrishnan, National Perinatal Epidemiology Unit, University of Oxford, Oxford OX3 7JX, United Kingdom			
First decision: December 12, 2021 Revised: December 24, 2021	<b>Peter Phiri</b> , Faculty of Environmental and Life Sciences, Psychology Department, University of Southampton, Southampton SO17 1PS, United Kingdom			
Accepted: April 9, 2022 Article in press: April 9, 2022 Published online: May 19, 2022	<b>Corresponding author:</b> Peter Phiri, BSc, PhD, RN, Academic Fellow, Department of Research and Innovation, Southern Health NHS Foundation Trust, Clinical Trials Facility, Moorgreen Hospital Botley Road, West End, Southampton SO30 3JB, United Kingdom.			
	peter.phiri@southernhealth.nhs.uk			
	Abstract			

# BACKGROUND

Over the last few decades, 3 pathogenic pandemics have impacted the global



population; severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. The global disease burden has attributed to millions of deaths and morbidities, with the majority being attributed to SARS-CoV-2. As such, the evaluation of the mental health (MH) impact across healthcare professionals (HCPs), patients and the general public would be an important facet to evaluate to better understand short, medium and long-term exposures.

# AIM

To identify and report: (1) MH conditions commonly observed across all 3 pandemics; (2) Impact of MH outcomes across HCPs, patients and the general public associated with all 3 pandemics; and (3) The prevalence of the MH impact and clinical epidemiological significance.

# **METHODS**

A systematic methodology was developed and published on PROSPERO (CRD42021228697). The databases PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of Controlled Trials were used as part of the data extraction process, and publications from January 1, 1990 to August 1, 2021 were searched. MeSH terms and keywords used included *Mood disorders, PTSD, Anxiety, Depression, Psychological stress, Psychosis, Bipolar, Mental Health, Unipolar, Self-harm, BAME, Psychiatry disorders and Psychological distress.* The terms were expanded with a 'snowballing' method. Cox-regression and the Monte-Carlo simulation method was used in addition to *I*<sup>2</sup> and Egger's tests to determine heterogeneity and publication bias.

# RESULTS

In comparison to MERS and SARS-CoV, it is evident SAR-CoV-2 has an ongoing MH impact, with emphasis on depression, anxiety and post-traumatic stress disorder.

# CONCLUSION

It was evident MH studies during MERS and SARS-CoV was limited in comparison to SARS-CoV-2, with much emphasis on reporting symptoms of depression, anxiety, stress and sleep disturbances. The lack of comprehensive studies conducted during previous pandemics have introduced limitations to the "know-how" for clinicians and researchers to better support patients and deliver care with limited healthcare resources.

**Key Words:** COVID-19; Middle East respiratory syndrome; SARS-CoV; SARS-CoV-2; Mental health; Wellbeing; Psychiatry; Healthcare professionals; Patients; Physical health; Public health; Outbreaks and pandemics

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Global research into exploring pandemics have been conducted for several decades. However, clinical research associated with mental health (MH) impact of Middle East respiratory syndrome, severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 was limited. This systematic review and meta-analysis is a comparison of the MH impact across, healthcare professionals, patients and the general public using the Monte-Carlo simulation method. Evaluated prevalence of multiple MH variables have been conducted using randomised controlled trials and cross-sectional studies. The study demonstrates the need to conduct comprehensive and longitudinal multi-morbid research to evaluate the true MH impact to aid better future pandemic preparedness. This systematic review and meta-analysis indicate a complex MH impact across all cohorts with the requirement for mechanistic relationships between physical and MH to be explored further.

**Citation**: Delanerolle G, Zeng Y, Shi JQ, Yeng X, Goodison W, Shetty A, Shetty S, Haque N, Elliot K, Ranaweera S, Ramakrishnan R, Raymont V, Rathod S, Phiri P. Mental health impact of the Middle East respiratory syndrome, SARS, and COVID-19: A comparative systematic review and meta-analysis. *World J Psychiatry* 2022; 12(5): 739-765

URL: https://www.wjgnet.com/2220-3206/full/v12/i5/739.htm DOI: https://dx.doi.org/10.5498/wjp.v12.i5.739

Zaishidena® WJP | https://www.wjgnet.com

# INTRODUCTION

Human civilisations have endeavoured various infectious diseases over centuries with multiple causatives, increases in population density, and increases in migration could attribute to increase in risk of emerging infectious diseases leading to global endemics and pandemics. Medicine in the modern era provide solutions to manage and mitigate infectious threats although there are many challenges associated with communicable and non-communicable diseases.

Fast forward to the 21st century, there have been three prominent outbreaks caused by novel coronaviruses[1]. The World Health Organisation (WHO) have classified two of these outbreaks as pandemics. Understanding the coronavirus family to prevent future pandemics would be useful.

The 2003 severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) comprised of the Middle East respiratory syndrome coronavirus (MERS-CoV) which includes a family of enveloped, single-stranded and diverse RNA viruses consisting of four genera: alpha, beta, gamma and delta ( $\alpha$ -,  $\beta$ -,  $\gamma$ - and  $\delta$ -*CoV*). Of these, alpha and beta-coronaviruses appear to be more deadly due to its ability to transmit across animals and humans, leading to stronger pathogens. Coronaviruses were first identified in 1965[2]. The SARS-CoV was the first outbreak in 2012. Neither of the outbreaks reached a pandemic status. Genetically similar to SARS-CoV, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), officially declared as a pandemic on March 11, 2020, continues to engulf global populations.

In comparison to the current SARS-CoV-2 pandemic, the SARS-CoV outbreak was effectively managed with aggressive public health measures amongst the countries affected<sup>[3]</sup>. Although, there are multi-factorial composites to consider to assess physical and mental health impact on the previous and current populations. For example, SARS-CoV reported an incidence and mortality of 8096 and 774 respectively across 29 countries[4].

In contrast, MERS-CoV outbreaks were reported across 27 countries between 2012-2019, mainly within the Middle East, with Saudi Arabia reporting majority of the cases based on WHO data[5]. However, incidence reporting of MERS-CoV over the last 7 years have been sporadic, indicating it is less contagious compared to the current SARS-CoV-2 infection. To date, there have been 2578 reported cases and 888 deaths due to MERS-CoV, with a crude mortality rate of around 34.4% [5]. Management of these infections primarily consist of public health measures to identify and isolate patients and effective infection control measures to reduce transmission rates[6]. Failures in effectively managing these outbreaks have primarily been attributed to the late identification of the disease. Secondary measures include quarantine failures due to non-disclosures by patients and poor communication between officials and the public[7,8].

Most patients with SARS-COV-2 are asymptomatic or develop mild symptoms[9]. However, for a small minority, they are likely to require admission to hospital with severe respiratory compromise which can lead to critical illness with respiratory failure and multiple organ failure[9]. These cases require high-level medical care within an intensive care unit (ICU) setting, including ventilatory support. Dexamethasone and Remdesivir are used alongside supportive measures and have proved effective in reducing mortality and hospital length of stay[10,11]. Interventions such as pruning, which has been recommended in the treatment of severe COVID-19 disease[12], have become common place in ICU settings, but is a labour-intensive procedure, putting further pressure on staff.

#### The global response to SARS-COV-2

The high degree of viral homology between SARS-COV-2 and previous coronavirus outbreaks directed the initial global response to the coronavirus disease 2019 (COVID-19) pandemic[13]. Given the relatively small population sizes involved in the first two novel coronavirus outbreaks, in addition to the geographical areas affected, the global understanding that shaped our response was probably limited in its scope. We recognise now it is in fact the differences, not the similarities, that have driven the rapid spread of the virus, including more prominent community spread and higher transmissibility of SARS-CoV-2, which includes asymptomatic and mildly symptomatic patients not seen in SARS-CoV [14].

#### The spread comparison between SARS-CoV, MERS-CoV and SARS-CoV-2

The characteristics of the emerging SARS-CoV-2 appears to be changing with the appearance of new variants, which is different to its predecessors, SARS-CoV and MERS-CoV. At the height of the SARS-CoV era, 140 new infections were reported per week, whilst current data suggest SARS-CoV-2 transmits approximately 100000 new infections per week during its peak period between February and May 2020 [15,16]. In addition to the common transmission network, viral shedding for SARS-CoV-2 in particular starts prior to symptom onset, which was the opposite with SARS-CoV. Therefore, quarantine measures would have been more effective during SARS-CoV in comparison to SARS-CoV-2.

#### The mental health impact of SARS-CoV-2

One of the long-term unknowns about the current pandemic is the physical manifestations and its impact on the mental health as well as the well-being of the public, patients and front-line healthcare professionals (HCPs). Experience from the previous novel coronavirus outbreaks suggests that the



psychological impacts will be widespread and long-lasting. Significant psychological symptomatology has been reported in the acute and early recovery phases associated with SARS-CoV[17-22] and MERS-CoV[17,23] in all three groups considered in this review. Importantly, when considering the long-term effects of this pandemic, the impact of the SARS-CoV pandemic was still recorded amongst infected individuals over four years after the reported outbreak, and in some cases with deteriorating symptoms [13].

The morphological and demographic features of the 3 viruses are vital to understand the mental health impact. Physical manifestations drive the mental health impact, often interacting as a planarian.

# MATERIALS AND METHODS

A systematic review protocol was designed, internally peer-reviewed and published on PROSPERO (CRD42021228697) with a comprehensive search strategy and data extraction method.

#### Research question/aims

This study has 3 primary aims of identifying and reporting: (1) Mental health (MH) conditions commonly observed across all 3 pandemics; (2) Impact of MH outcomes across HCPs, patients and the general public associated with all 3 pandemics; and (3) The prevalence of the MH impact and clinical epidemiological significance.

#### Data searches

Multiple databases of PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of Controlled Trials were used to extract relevant data. MeSH terms and keywords used included *Mood disorders*, *PTSD*, *Anxiety*, *Depression*, *Psychological stress*, *Psychosis*, *Bipolar*, *Mental Health*, *Unipolar*, *Self-harm*, *BAME* (*Black*, *Asian and Minority Ethnic*), *Psychiatry disorders* and *Psychological distress*. The terms were expanded with a 'snowball' method that has been demonstrated with a PRISMA diagram. All publications that were peer-reviewed in English were included. The final dataset was reviewed independently before the analysis was conducted.

#### Data synthesis

The data synthesis is based on the statistical data extracted from the studies included based on the eligibility criteria developed. This includes data associated with the mean  $\pm$  SD and median along with  $q_1$  (25% quantile) and  $q_3$  (75% quantile). Q1 and  $q_3$  are novel estimation methods used to improve existing meta-analysis as demonstrated by Wan and colleagues[24]. Most of the studies identified reported multiple MH outcomes such as depression, anxiety and psychological distress among people who experienced MERS, SARS-CoV and SARS-CoV-2. For studies that reported the median along with  $q_1$  and  $q_3$ , the mean  $\pm$  SD of the studies were estimated from the median,  $q_1$  and  $q_3$ . Therefore, the following equation was used to analyse the data, where the  $\Phi^{-1}$  represented the inverse of the standard normal distribution, as described below.

Most MERS-CoV studies only reported SD. Some studies included the median only, and these were transformed to  $q_1$  and  $q_3$ , where the mean  $\pm$  SD were estimated using the Monte-Carlo simulation method, with the cut off scores of the MH assessments used within the studies. This data was assumed to be normally distributed. Random effects models were used to conduct the meta-analysis to estimate the pooled prevalence. MH assessments reported within the studies included the Impact of Event Scale-Revised (IES-R), Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire (PHQ-9), Short Form 36 Health Survey (SF-36), General Anxiety Disorder (GAD-7) and State-Trait Anger Expression Inventory (STAXI). For this we assumed normal distribution of the data. A subgroup analysis was conducted to evaluate any identified heterogeneity. Funnel plots and Egger's tests were performed to demonstrate publication bias and a sensitivity analysis. A comparative analysis was conducted using the SAR-CoV and SARS-CoV-2 data published by Chau *et al*[25].

The full data analysis was conducted using the STATA 16.1 software application.

#### Risk of bias quality assessment

A quality assessment was performed using the Newcastle-Ottawa-Scale (NOS) for studies included systematically (Supplementary Table 1). The NOS is an eight-item scale with three quality parameters: (1) Selection; (2) Comparability; and (3) Outcome. We rated the quality of the studies (good, fair and poor) by allocating each domain with stars in this manner: (1) A Good quality score was awarded 3 or 4 stars in selection, 1 or 2 in comparability, and 2 or 3 stars in outcomes; (2) A Fair quality score was awarded 2 stars in selection, 1 or 2 stars in comparability, and 2 or 3 stars in outcomes; and (3) A Poor quality score was allocated 0 or 1 star(s) in selection, 0 stars in comparability, and 0 or 1 star(s) in outcomes domain.

Zaishidena® WJP | https://www.wjgnet.com

### RESULTS

The comprehensive multiple database literature search included publications from January 1, 1990 to August 1, 2021. The PRISMA diagram reflects the total yielded studies and systematic inclusions prior to the completion of the meta-analysis as shown in Figure 1.

#### MERS-CoV

A total of 58 studies were included in the systematic review for MERS as shown in Supplementary Table 2. The search for MERS-CoV yielded 14, 144 of which 152 articles met the inclusion criteria to be reviewed by title and abstract. Eleven duplicates were removed. A further 29 studies were excluded as these were not pertinent to the MERS-CoV demonstrating MH outcomes, and 38 studies were excluded due to the lack of statistical data. Fifteen articles that were not published in English was also excluded. Therefore, the meta-analysis was conducted on 21 studies as demonstrated in Table 1.

#### SARS-CoV

In relation to the SARS-CoV, the systematic review was conducted on 80 studies, as detailed in Supplementary Table 3, and the meta-analysis included 39 studies, as shown in Table 2.

#### SARS-CoV-2

A total of 513 studies were included in the systematic review for SARS-CoV-2, as shown in Supplementary Table 4. 287 of these studies are from the meta-analysis conducted by Phiri *et al*[26]. The meta-analysis was conducted on 188 studies, as demonstrated in Supplementary Table 5.

#### Meta-analysis

**Anxiety:** Eight studies reported the prevalence of anxiety during the MERS-CoV outbreak. As demonstrated by Figure 2, the pooled prevalence of anxiety was 17.35% with a 95% confidence interval (CI): 8.36-36.02. A heterogeneity of  $l^2 = 95.62\%$  was identified.

The systematic review indicates 14 studies report the prevalence of anxiety during SARS-CoV, although only 9 report the mean  $\pm$  SD. Twenty-three studies were included into the meta-analysis. Figure 3 indicates the prevalence of anxiety during SARS-CoV where the pooled prevalence was 25.2%, with a 95%CI of 18.41-34.5. A high heterogeneity of  $I^2$  = 93.47% was identified.

The systematic review identified 175 studies that reported anxiety as an outcome due to SARS-CoV-2 where 40 studies provided mean and SD. By utilizing the Monte-Carlo simulation on the studies that only provide mean and SD, we obtained twenty-five studies that reported the prevalence of anxiety. As for the anxiety resulting from SARS-CoV-2, Figure 4 shows a pooled prevalence of 21.44% with a 95%CI of 18.69-24.61. However, a high heterogeneity of 99.77% was identified.

Based on these results, the prevalence of anxiety during SARS-CoV is more significant in comparison to MERS-CoV and SARS-CoV-2.

#### Depression

The systematic search for MERS-CoV yielded seven studies reporting depression. The meta-analysis is demonstrated in Figure 5 and shows a pooled prevalence of 33.65%. The 95%CI ranged between 22.02-51.42. A moderate heterogeneity of at  $l^2$  = 69.86% was identified.

Thirty-eight studies reported the prevalence of depression during the SARS-CoV outbreak. Of these, 23 reported prevalence directly and 15 demonstrated the mean score and SD instead. By using the Monte-Carlo simulation method, thirty-eight results were meta-analysed as demonstrated in Figure 6. The pooled prevalence of depression during the pandemic of SARS-CoV was 23.1%, while the 95%CI was between 18.14-29.4. A high heterogeneity was calculated at  $l^2 = 95.03\%$ .

One hundred and twenty-three studies reported on depression during SARS-CoV-2. Of these, 102 reported the prevalence of depression directly and 21 demonstrated mean and SD values only. Figure 7 indicates the pooled prevalence of depression during SARS-CoV-2 was 27.68%, with a 95%CI ranging from 24.67-31.06. A high heterogeneity of  $l^2$  = 99.71% was identified.

Based on the analysis, MERS-CoV and SARS-CoV-2 appear to report the highest levels of depression based on the pooled prevalence of 27.64% and 33.65% respectively.

#### Post-traumatic stress disorder

Twenty-seven studies reported post-traumatic stress disorder (PTSD) during the MERS-CoV outbreak. Figure 8 demonstrated a pooled prevalence of 35.97%, with a relatively moderate to high heterogeneity of P = 75.2% and a 95%CI ranging between 29.60-43.72.

Sixty-four of the studies identified had reported on the prevalence of PTSD during SARS-CoV. Of these, 48 studies reported on the prevalence directly, whilst 17 demonstrated the mean score and the corresponding SD. Figure 9 shows the pooled prevalence of PTSD was 18.2% with a CI of 14.94-22.18 and an elevated heterogeneity of  $l^2$  = 91.37%.

#### Table 1 21 studies that are included in meta-analysis for Middle East respiratory syndrome

Study ID	Ref.	Study type	Sample size	Country	Exposure	Outcome	<i>P</i> value	Quality assessment (NOS)
1	Shin <i>et al</i> [36]	Quantitative	63	Korea	MERS patients	PTSD, Sleep problem, anxiety, depression, suicidality, phobic anxiety, addiction, aggression	Not specified	7
2	Um et al[ <mark>37</mark> ]	Quantitative	64	Korea	MERS patients and HCWs	PTSD, depression	Not specified	7
3	Abolfotouh <i>et</i> al[38]	Quantitative	1031	Saudi Arabia	HCWs	Level of Concern	Not specified	7
4	Jung et al[ <mark>39</mark> ]	Quantitative	147	Korea	HCWs	PTSD	Not specified	6
5	Ahn et al[40]	Quantitative	63	Korea	MERS Patients	Suicide, fatigue	Not specified	6
6	Lee <i>et al</i> [41]	Quantitative	52	Korea	MERS Patients	Depression, PTSD, fatigue	Not specified	6
7	Kim et al[42]	Quantitative	112	Korea	HCWs	PTSD, burnout	Not specified	7
8	Oh et al[ <mark>43</mark> ]	Quantitative	313	Korea	HCWs	Stress	Stress: 0.066	7
9	Seo et al[44]	Quantitative	171	Korea	HCWs	Burnout	Not specified	5
10	Son et al[45]	Quantitative	280	Korea	HCWs and general public	PTSD	Not specified	6
11	Park et al[46]	Quantitative	187	Korea	HCWs	Stress	Not specified	6
12	Jeong et al[24]	Qualitative	1692	Korea	MERS patients and general public	Anxiety	Not specified	7
13	Al-Rabiaah et al[ <mark>47</mark> ]	Quantitative	174	Saudi Arabia	General public	Anxiety	Not specified	7
14	Park et al[48]	Quantitative	63	Korea	MERS Patients	PTSD, depression	Not specified	7
15	Cho et al[49]	Quantitative	111	Korea	General public	PTSD	PTSD: 0.3	7
16	Kim et al[50]	Quantitative	27	Korea	General public	Depression	Not specified	5
17	Lee et al[51]	Quantitative	359	Korea	HCWs	PTSD	Not specified	6
18	Kim and Choi[ <mark>52</mark> ]	Quantitative	215	Korea	HCWs	Burnout, stress	Not specified	6
19	Bukhari <i>et al</i> [53]	Quantitative	386	Saudi Arabia	HCWs	Worry	Not specified	6
20	Mollers <i>et al</i> [54]	Quantitative	72	Netherlands	General public	PTSD	Not specified	5
21	Kim and Choi[ <mark>52</mark> ]	Quantitative	215	Korea	HCWs	PTSD: 0.017	PTSD: 0.017	6

PTSD: Post-traumatic stress disorder; MERS: Middle East respiratory syndrome; HCW: Healthcare worker.

Nineteen studies reported the prevalence of PTSD during SARS-CoV-2. Figure 10 indicates a pooled prevalence of PTSD of 25.03% with a 95%CI ranging between 18.15-34.51. A high heterogeneity of  $l^2$  = 99.58% was identified.

Based on the findings, PTSD appears to have been reported for SARS-CoV-2, MERS-CoV and SARS-CoV.

A comparative analysis was completed for each MH variable identified and reported, as demonstrated within Tables 3-5.



# Table 2 39 studies that are included in meta-analysis for severe acute respiratory syndrome

Study ID	Ref.	Study type	Sample size	Country/region	Exposure	<i>P</i> value	Quality assessment (NOS)
1	Kwek <i>et al</i> [20]	Cross-sectional	360	Singapore	SARS patients	PTSD: 0.79; Depression: 0.7; Anxiety: 0.51	7
2	Fang et al[55]	Cross-sectional	1278	China	SARS patients	Anxiety: 0.291; Depression: 0.705; PTSD: 0.2	8
3	Liang[ <mark>56</mark> ]	Prospective cohort	769	China, Taiwan	SARS patients	PTSD: > 0.05; Anxiety: > 0.05	7
4	Dang et al[ <mark>57</mark> ]	Cross-sectional	549	China	General public	Anxiety: < 0.00001; Depression: 0.000361	7
5	Yip[58]	Prospective cohort	218	China, Hong Kong	SARS patients	Not specified	6
6	Cheng <i>et al</i> [ <mark>59</mark> ]	Cross-sectional	10	China, Hong Kong	SARS patients	Anxiety: > 0.05; Depression: > 0.05	5
7	Wu et al[ <mark>60</mark> ]	Cross-sectional	286	China, Hong Kong	SARS patients	PTSD: < 0.001; Depression: < 0.05; Anxiety: < 0.01	6
8	MaK et al <mark>[61</mark> ]	Retrospective cohort	126	China, Hong Kong	SARS patients	Not specified	5
9	Lee et al[62]	Cross-sectional	10511	China, Hong Kong	Were not HCWs	Not specified	7
10	Hong et al[63]	Cross-sectional	1050	China	SARS patients	PTSD: 0.0323	7
11	Wang[64]	Prospective cohort	22	China	SARS patients	Not specified	4
12	Hu et al[65]	Cross-sectional	763	China	Attended hospital for other reasons	Not specified	5
13	Chen et al[66]	Prospective cohort	325	China, Taiwan	Non-infected HCWs in the largest obligatory SARS hospital, with high SARS contact	Anxiety: 0.55 Depression: 0.93	6
14	Ko et al <mark>[67</mark> ]	Cross-sectional	72	China, Taiwan	General public of outbreak area	Depression: 0.02	5
15	Lee et al[21]	Cross-sectional	114	China, Hong Kong	General public of outbreak area	Not specified	6
16	Hawryluck et al[ <mark>68</mark> ]	Cross-sectional	652	Canada, Toronto	General public of outbreak area	Depression: 0.85; PTSD: 0.82	7
17	Liu et al <mark>[69</mark> ]	Cross-sectional	96	China, Beijing	Non-infected HCWs of SARS hospital	Depression: < 0.05	7
18	Su <i>et al</i> [70]	Prospective cohort	57	China, Taiwan	Non-infected HCWs in SARS outbreak region with high exposure risk <i>vs</i> low exposure risk	PTSD: > 0.05; Depression: < 0.05	7
19	Lam et al[ <mark>71</mark> ]	Retrospective cohort	116	China, Hong Kong	SARS patients	Not specified	6
20	Shi et al[72]	Prospective cohort	87	China, Beijing	SARS outbreak region	Not specified	5
21	Huang et al [73]	Cross-sectional	4481	China, Beijing	Were not HCWs	Not specified	6
22	Yu et al <mark>[74</mark> ]	Prospective cohort	180	China, Hong Kong	General public of outbreak area	Not specified	5
23	Chang and Sivam[ <mark>75</mark> ]	Cross-sectional	146	Singapore	General public of outbreak area	Not specified	5
24	Moldofsky and Patcai[76]	Retrospective cohort	107	Canada, Toronto	SARS patients, who were HCWs	Not specified	6
25	Sun et al[77]	Prospective cohort	1557	China, Xianxi	SARS patients	PTSD: 0.67	7
26	Lau et al <mark>[78]</mark>	Cross-sectional	333	China, Hong Kong	General public of outbreak area	Not specified	5



#### Delanerolle G et al. EPIC MERS\_SARS\_COVID-19 comparator

27	Reynolds <i>et al</i> [79]	Cross-sectional	89	Canada	General public of outbreak area, quarantined; non-infected HCWs in SARS outbreak region, quarantined	Not specified	5
28	Lancee <i>et al</i> [80]	Cross-sectional	613	Canada, Toronto	Non-infected HCWs in SARS outbreak region	Not specified	6
29	Lin <i>et al</i> [81]	Cross-sectional	6280	China, Taiwan, Taichung	Non-infected HCWs in in region without major SARS outbreak	Not specified	6
30	Gao et al[ <mark>82</mark> ]	Prospective cohort	127	China, Tianjin	SARS patients	Not specified	5
31	Xu et al <mark>[83</mark> ]	Cross-sectional	129	China, Xianxi	Non-infected HCWs in SARS hospital	PTSD: > 0.05	6
32	Wong et al[84]	Cross-sectional	0 (?)	China, Hong Kong	Non-infected HCWs from SARS hospitals	Not specified	4
33	Sim et al[85]	Cross-sectional	90	Singapore	Non-infected HCWs in SARS outbreak region	Not specified	5
34	Wu et al[19]	Cross-sectional	133	China, Beijing	Non-infected HCWs in SARS hospital	Not specified	6
35	Chen <i>et al</i> [ <mark>86</mark> ]	Cross-sectional	103	China, Taiwan, Kaohsiung	Non-infected HCWs in SARS hospital, with high SARS contact; non-infected HCWs in SARS hospital; with low SARS contact	Not specified	6
36	Tham <i>et al</i> [ <mark>87</mark> ]	Cross-sectional	90	Singapore	Non-infected HCWs in SARS hospital with extra risk of exposure	Not specified	5
37	Maunder <i>et al</i> [ <mark>88</mark> ]	Cross-sectional	90	Canada, Toronto	Non-infected HCWs of outbreak area, unspecified (mix of SARS affected and non SARS affected hospitals	PTSD: < 0.01	7
38	Mak et al[ <mark>89</mark> ]	Retrospective cohort	126	China, Hong Kong	SARS patient	Not specified	6
39	McAlonan et al[90]	Cross-sectional	0 (?)	China, Hong Kong	Non-infected HCWs in SARS outbreak region with high exposure risk <i>vs</i> low exposure risk	Not specified	3

PTSD: Post-traumatic stress disorder; MERS: Middle East respiratory syndrome; HCW: Healthcare worker; CI: Confidence interval; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.

Table 3 Pooled prevalence and confidence interval of anxiety across Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2

Anxiety	Prevalence (%)	95%CI	Heterogeneity /² (%)
MERS	17.35	8.36-36.02	95.62
SARS-CoV-2	21.48	18.68-24.71	99.76
SARS-CoV	25.20	18.41-34.5	93.47

CI: Confidence interval; MERS: Middle East respiratory syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.

Table 4 Pooled prevalence and confidence interval of depression across three diseases						
Depression         Prevalence (%)         95%Cl         Heterogeneity f (%)						
MERS	33.65	22.02-51.42	69.86			
SARS-CoV-2	27.64	24.59-31.06	99.69			
SARS-CoV	23.10	18.14-29.4	95.03			

CI: Confidence interval; MERS: Middle East respiratory syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.



Boishideng® WJP https://www.wjgnet.com

# Subgroup analysis

Multiple subgroup analyses using age group, cohort and location were conducted as an aim to identify the causation of the heterogeneity reported throughout the meta-analyses.

# Age

SARS-CoV-2: The subgroup analysis of age includes 10-19, 20-29, 30-39, 40-49, 50-59, 60-69 (Supplementary Figure 1). In particular, it can be seen from Supplementary Figure 2 that the pooled prevalence for 10-19 year-olds who are likely to have depression due to SARS-CoV-2 is 24.42%. The pooled prevalence for 60-69 years old, on the other hand, was 7.75% with a lower prevalence of depression. Therefore, the details from these analyses demonstrate the statistically reported heterogeneity could be due to the inclusion of multiple age groups.

This is further demonstrated in Supplementary Figure 3, where similar results are indicated for those reporting PTSD among young people, which appears to be higher than the older population (for instance, 32.40% for 20-29 group compared while 5.38% for 50-59 group). However, this is still reflective of a high heterogeneity which could be attributed to the differences in body mass index or race, although, to make a conclusion, further research data is required.

SARS-CoV: The subgroup analysis based on age for the SARS-CoV indicate the prevalence of mental health issues in different age groups during SARS. Supplementary Figure 4 demonstrated that people from 50 to 59 years of age appear to have a higher risk of anxiety (51.62%) in comparison to those between 30-39 (27.4%) as indicated in Supplementary Figure 5. The prevalence of PTSD (Supplementary Figure 6) indicates people within the 30-39 age group report a relatively high risk (32.13%) of PTSD in comparison to those of 60-69 years of age. However, the age group of 60-69 years was based on a single study.

Comparison: Based on the comparison between the 3 meta-analyses, the following results associated with MH outcomes are as indicated within Tables 6-8.

# Cohort

SARS-CoV-2: Another facet of the subgroup analysis was based upon the cohorts included within this study, of HCPs, patients and the general public. The MH outcomes are demonstrated in Supplementary Figures 7-9. It is evident that healthcare workers (HCWs) have a higher prevalence of anxiety and depression compared to the general public. The exception to this appears to be the prevalence of PTSD, where the levels appear to be similar for the public and HCWs, at 24.83% and 25.16% respectively.

MERS: Supplementary Figure 10 demonstrates that the general public consists of a smaller pooled prevalence (6.04%) for the MH outcome of anxiety in comparison to patients who contracted MERS-CoV (33.95%), although some of these patients could very well be HCWs themselves. On the contrary, the pooled data for the general public and MERS-CoV survivors indicate a relatively high prevalence of depression (40.7% and 41.69%), while the HCWs appear less likely to have depression (20.52%), as indicated by Supplementary Figure 11. Mild heterogeneity was detected across these 2 groups, with  $l^2$ scores of 41.71%,  $I^2 = 71.77\%$ . Therefore, statistically, the data and subsequent results appear to be more conclusive and reliable. Supplementary Figure 12 indicated the prevalence of PTSD between HCWs and the general public. PTSD within the general public appears to be relatively low (19.02%) in comparison to depression. Additionally, depression amongst HCWs is more prevalent (49.87%). Moreover, the heterogeneity ( $I^2 = 0$ ) of this subgroup analysis is negligible, which demonstrates the data are statistically reliable and the conclusions are therefore more conclusive.

SARS-CoV: The subgroup analysis within the SARS-CoV group demonstrated a much higher prevalence of anxiety within HCWs (98.44%) in comparison to the general public (26.19%), as indicated in Supplementary Figure 12. Supplementary Figure 13 indicates that HCWs have a higher prevalence of depression (25.42%) than general public (23.31%) and SARS-CoV patients (21.96%). In contrast, the prevalence of PTSD among HCWs appear to be relatively low (16.97%) in comparison to SARS-CoV patients (19.80%) as well as the general public (18.36%), as indicated in Supplementary Figure 14. However, the heterogeneity score  $l^2$  remains high, thus there may be other potential factors that may affect the statistical findings.

**Comparison:** Based on the subgroup analysis above, Tables 9-11 showcase the prevalence of different MH outcomes among various cohorts. There are similarities and differences. The prevalence of anxiety within the general public during MERS (6.04%) is the lowest across the three outbreaks, while SARS-CoV demonstrates the largest prevalence of anxiety within general public (26.19%). Meanwhile, HCWs who experienced SARS-CoV were likely to have anxiety (98.44%). The prevalence of anxiety within MERS-CoV patients (33.95%) appear to be the most commonly reported MH outcome. MERS-CoV also demonstrates the highest prevalence of depression within the general public and patients, at 40.70% and 41.69% respectively. Based on the current data on SARS-CoV-2, HCWs are more likely to suffer from depression (37.97%). The highest levels of PTSD were found in HCWs during MERS-CoV and MERS-



#### Delanerolle G et al. EPIC MERS\_SARS\_COVID-19 comparator

Table 5 Pooled prevalence and confidence interval of post-traumatic stress disorder across three diseases						
PTSD Prevalence (%) 95%Cl Heterogeneity F (%)						
MERS	35.97	29.6-43.72	75.2			
SARS-CoV-2	25.03	18.15-34.51	99.58			
SARS-CoV	18.20	14.94-22.18	91.37			

PTSD: Post-traumatic stress disorder; CI: Confidence interval; MERS: Middle East respiratory syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.

#### Table 6 Subgroup analysis on Middle East respiratory syndrome data based on different age groups

Subaroup ago	MERS				
Subgroup-age		Prevalence (%)	95%CI	Heterogeneity P (%)	
Anxiety	10-19	-	-	-	
	20-29	-	-	-	
	30-39	-	-	-	
	40-49	18.51	8.11-42.23	96.43	
	50-59	-	-	-	
Depression	20-29	-	-	-	
	30-39	-	-	-	
	40-49	38.45	25.81-57.26	60.55	
	50-59	-	-	-	
PTSD	20-29	49.70	38.2-64.67	0	
	30-39	19.32	14.82-25.18	0	
	40-49	26.69	13.21-53.91	80.63	
	50-59	-	-	-	
	60-69	17.87	12.4-25.74	0	

MERS: Middle East respiratory syndrome; PTSD: Post-traumatic stress disorder; CI: Confidence interval.

CoV patients (49.87% and 37.7%). SARS-CoV-2 appears to demonstrate that PTSD was experienced by 24.83% the general public.

From Supplementary Figures 15-17 we can see that people who experience MERS are more likely to have depression and PTSD than those who experience SARS-CoV-2 and SARS-CoV (the area of the MERS triangles in Supplementary Figures 15 and 17 are larger than the area of the SARS-CoV-2 and SARS-CoV triangles) while people who experience SARS-CoV may have a higher possibility to have anxiety than the other two (the area of the SARS-CoV triangle in Supplementary Figure 16 is larger the area of the MERS and SARS-CoV2 triangles).

#### Occupation

SARS-CoV-2: Another facet of the subgroup analysis was based upon the occupation of the sample and the reporting of MH outcomes as demonstrated in Supplementary Figures 7-9. It is evident that HCWs have a higher prevalence of anxiety and depression compared to the general public. The exception to this appears to be the prevalence of PTSD, where the levels appear to be similar between the public and HCWs, at 24.83% and 25.16% respectively.

MERS: A subgroup analysis based upon the categories of HCWs, patients and the general public associated with the prevalence of MH outcomes further demonstrates variability. Supplementary Figure 10, for example, demonstrates that the general public is consistent with a smaller pooled prevalence (6.04%) for the MH outcome of anxiety in comparison to patients who contracted MERS-CoV (33.95%), although some of these patients could very well be HCWs themselves. On the contrary, the pooled data for the general public and MERS-CoV survivors indicate a relatively high level of



Table 7 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different age groups							
0. h	SARS-CoV-	SARS-CoV-2					
Subgroup-age		Prevalence (%)	95%CI	Heterogeneity P (%)			
Anxiety	10-19	34.40	33.17-35.68	0			
	20-29	25.70	19.38-34.08	99.25			
	30-39	22.86	17.86-29.26	99.64			
	40-49	15.59	9.65-25.17	99.66			
	50-59	20.13	10.43-38.84	99.42			
	60-69	7.75	0.79-76.29	99.47			
Depression	10-19	43.91	42.12-45.77	0			
	20-29	31.03	24.04-40.04	99.12			
	30-39	30.4	25.15-36.74	99.48			
	40-49	20.0	13.26-30.18	99.4			
	50-59	19.98	15.84-25.19	92.68			
	60-69	4.93	3.45-7.05	90.00			
PTSD	20-29	32.40	6.54-160.49	98.29			
	30-39	21.96	12.77-37.78	99.33			
	40-49	27.72	19.88-38.66	97.59			
	50-59	5.38	3.76-7.69	0			
	60-69	-	-	-			

SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; PTSD: Post-traumatic stress disorder; CI: Confidence interval.

# Table 8 Subgroup analysis on severe acute respiratory syndrome coronavirus data based on different age groups

Subaroup ago	SARS-CoV					
Subgroup-age		Prevalence (%)	95%CI	Heterogeneity <i>P</i> (%)		
Anxiety	10-19	-	-	-		
	20-29	-	-			
	30-39	24.60	13.29-45.55	85.81		
	40-49	15.63	10.97-22.26	60.57		
	50-59	51.62	38.53-69.16	0		
Depression	20-29	-	-	-		
	30-39	27.47	16.09-46.9	89.58		
	40-49	20.30	13.36-30.85	81.57		
	50-59	22.49	14.8-34.17	0		
	60-69	25.85	17.69-37.75	0		
PTSD	20-29	24.43	15.53-38.44	72.18		
	30-39	32.13	23.1-44.68	89.33		
	40-49	11.68	8.45-16.15	86.20		
	50-59	67.80	43.57-100	0		
	60-69	7.54	2.64-21.54	53.28		

SARS-CoV: Severe acute respiratory syndrome coronavirus; PTSD: Post-traumatic stress disorder; CI: Confidence interval.

Baisbideng® WJP | https://www.wjgnet.com

### Table 9 Subgroup analysis on Middle East respiratory syndrome data based on different type of people

Subgroup accuration	MERS					
Subgroup-occupation		Prevalence (%)	95%CI	Heterogeneity P (%)		
Anxiety	General Public	6.04	2.86-12.79	93.9		
	HCW	-	-	-		
	Patient	33.95	20.65-55.82	68.57		
Depression	General Public	40.70	18.89-87.71	0		
	HCW	20.52	11.81-35.67	41.71		
	Patient	41.69	23.73-73.22	71.77		
PTSD	General Public	19.02	14.01-25.81	0		
	HCW	49.87	45.09-55.16	0		
	Patient	37.70	27.47-51.74	0		

MERS: Middle East respiratory syndrome; HCW: Healthcare worker; PTSD: Post-traumatic stress disorder; CI: Confidence interval.

#### Table 10 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different type of people

Subarous connetion	SARS-CoV-2					
Subgroup-occupation		Prevalence (%)	95%CI	Heterogeneity P (%)		
Anxiety	General Public	21.18	17.88-25.09	99.82		
	HCW	22.35	17.42-28.66	99.36		
	Patient	-	-	-		
Depression	General Public	27.6	23.36-32.24	99.8		
	HCW	27.71	23.22-33.08	98.79		
	Patient	-	-	-		
PTSD	General Public	24.83	14.97-41.18	99.67		
	HCW	25.16	16.62-38.08	99.33		
	Patient	-	-	-		

SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; HCW: Healthcare worker; PTSD: Post-traumatic stress disorder; CI: Confidence interval.

prevalence (40.7% and 41.69%) of depression, while the HCWs appear less likely to have depression (20.52%), as indicated by Supplementary Figure 11. Mild heterogeneity was detected across these 2 groups, with  $l^2$  scores of 41.71%,  $l^2 = 71.77$ %. Therefore, statistically, the data and subsequent results appear to be more conclusive and reliable. Supplementary Figure 12 indicated the prevalence of PTSD between HCWs and the general public. PTSD within the general public appears to be relatively low (19.02%) in comparison to depression. Additionally, depression is more prevalent in HCWs (49.87%). Moreover, the heterogeneity  $l^2 = 0$  of this subgroup analysis is negligible, which demonstrates the data are statistically reliable and the conclusions are therefore more conclusive.

SARS-CoV: The subgroup analysis within the SARS-CoV group demonstrated a much higher prevalence of anxiety within HCWs (98.44%) in comparison to the general public (26.19%), as indicated in Supplementary Figure 13. Supplementary Figure 14 indicates that HCWs have a higher prevalence of depression (25.42%) than the general public (21.96%) and SARS-CoV patients (23.31%). In contrast, the prevalence of PTSD among HCWs appear to be relatively low (16.97%) in comparison to SARS-CoV patients (19.80%) as well as the general public (18.36%), as indicated in Supplementary Figure 15. However, the heterogeneity score  $l^2$  remains high, thus there may be other potential factors that may affect the statistical findings.


It can be seen from Supplementary Figure 15 that it is less likely for people who experience SARS-CoV to have depression, while people who experience MERS are the most likely to suffer from depression. In particular, the general public and MERS patients have a greater risk of depression than



# Table 11 Subgroup analysis on studies under severe acute respiratory syndrome coronavirus data based on different type of people

Subarous connetion	SARS-CoV										
Subgroup-occupation		Prevalence (%)	95%CI	Heterogeneity /² (%)							
Anxiety	General Public	26.19	11.93-57.48	98.22							
	HCW	98.44	22.67-427.49	0							
	Patient	24.21	17.34-33.79	85.16							
Depression	General Public	23.31	14.64-37.11	97.97							
	HCW	25.42	13.74-47.03	90.29							
	Patient	21.96	16.86-28.6	78.1							
PTSD	General Public	18.36	13.59-24.81	81.69							
	HCW	16.97	12.28-23.45	91.8							
	Patient	19.80	14.28-27.46	90.44							

SARS-CoV: Severe acute respiratory syndrome coronavirus; HCW: Healthcare worker; PTSD: Post-traumatic stress disorder; CI: Confidence interval.



DOI: 10.5498/wjp.v12.i5.739 Copyright ©The Author(s) 2022.

Figure 1 PRISMA flow diagram. MERS: Middle East respiratory syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; COVID-19: Coronavirus disease 2019.

> those who experience SARS-CoV-2 and SARS-CoV. However, people in the outbreak of SARS-CoV are more likely to have anxiety than people in the outbreak of MERS and SARS-CoV-2 (Supplementary Figure 16). Moreover, it can be noted from Supplementary Figure 16 that HCWs, during the outbreak of SARS-CoV, endured a very high risk of having anxiety. When it comes to PTSD, Supplementary Figure 17 shows that MERS leads to the highest prevalence of PTSD in almost all the mental health diseases across the three pandemics. In particular, HCWs and MERS patients suffer from a serious risk of PSTD after MERS. On the other hand, SARS-CoV seems to lead a relative low risk on the prevalence of PTSD.





Figure 2 Forest plot of anxiety caused by Middle East respiratory syndrome.



Random-effects REML model

DOI: 10.5498/wjp.v12.i5.739 Copyright ©The Author(s) 2022.

Figure 3 Forest plot of anxiety that is caused by severe acute respiratory syndrome coronavirus.

Zaishidena® WJP | https://www.wjgnet.com

#### Delanerolle G et al. EPIC MERS\_SARS\_COVID-19 comparator

Study Sun et al, 2020	Study Size			(%)	Shah et al, 2020	207	_		4.60 [ 17.93, 33.75] 0.58			_		16.30 [ 13.15, 20.20] 0.59		2794	=		5.32, 7.23] 0.5
Sun et al, 2020	500	-	0.07/ 0.00 / 10		Than et al, 2020	173	-	33.	3.50 [ 24.43, 45.94] 0.58	Creese et al, 2020	3281		_	2.70 [ 2.19, 3.33] 0.59		2766	• •		5.50, 7.45] 0.5
	536 —	•	0.37 [ 0.09, 1.49]		Civantos et al, 2020	163		45.	5.50 [ 33.43, 61.93] 0.58	Shetchter et al, 2020	361			40.00 [ 32.41, 49.38] 0.59	•	709	_		32.65, 44.22] 0.5
Lu et al, 2020	257		1.17 [ 0.38, 3.65]		Suryavanshi et al, 2020	197	-	29.	9.00 [ 21.32, 39.45] 0.58	He et al, 2020	374			41.20 [ 33.53, 50.62] 0.59	•	1385			12.12, 16.40] 0.5
Rapisarda et al, 2020	241		2.07 [ 0.85, 5.02]		Trumello et al, 2020	306	-	15.	5.99 [ 11.78, 21.71] 0.58	He et al, 2020	403			35.70 [ 29.12, 43.77] 0.59		678	_	-	(3.87, 59.29] 0.5
Ma et al, 2020	34		35.00 [ 17.30, 70.81]		Pan et al, 2020	194	-	32.	2.50 [ 24.07, 43.89] 0.58	Juan et al, 2020	456		_	31.60 [ 25.94, 38.50] 0.59		2291			6.99, 9.43] 0.5
McKay et al, 2020	908	- <b>-</b>	0.88 [ 0.44, 1.77]		Lu et al, 2020	2042		2.	2.20 [ 1.64, 2.96] 0.58	Hyun et al, 2020	908			13.11 [ 10.81, 15.90] 0.59		695			7.28, 63.75] 0.5
Mahyijari et al, 2020	150		6.67 [ 3.51, 12.67]		Chew et al, 2021	200	-	36.	6.50 [ 27.37, 48.68] 0.58	Cheng et al, 2020	435			42.00 [ 34.72, 50.81] 0.59		846			25.45, 34.20] 0.5
Puccinelli et al, 2021	57	-	22.80 [ 12.28, 42.33]		Dawel et al, 2020	1296		3.	3.78 [ 2.84, 5.03] 0.58	Cenat et al, 2021	1267			9.41 [ 7.79, 11.36] 0.59		1267			14.38, 19.32] 0.5
Hamm et al, 2020	73	_			Li et al, 2020	225	-	35.	5.60 [ 27.10, 46.77] 0.58	Zalzaid et al, 2020	441			48.10 [ 39.90, 57.98] 0.59	Wang et al, 2020	1397		15.20 [ 1	13.13, 17.59] 0.5
Magnavita et al, 2020	90	-	- 15.56 [ 8.80, 27.51]		Setiawti et al, 2021	227	-	39.	9.60 [ 30.35, 51.67] 0.58	Faulker et al, 2020	8425			1.44 [ 1.20, 1.72] 0.59	Kar et al, 2020	733		47.50 [ 4	1.09, 54.91] 0.5
Puccinelli et al, 2021	57		- 64.90 [ 37.67, 111.81]		Setiawti et al, 2021	227		43.	3.60 [ 33.54, 56.68] 0.58	Sediri et al, 2020	751			79.20 [ 66.40, 94.46] 0.59		1071			19.04, 25.42] 0.5
Yang et al, 2020	54	_	- 50.00 [ 29.33, 85.24]		Zhao et al, 2020	515		14.	4.40 [ 11.26, 18.42] 0.58	Hazarika et al, 2021	541			35.50 [ 29.77, 42.34] 0.59		2530			6.91, 9.21] 0.5
Shetchter et al, 2020	141	1	15.00 [ 9.45, 23.81]		Mekonen et al, 2020	302		69.	9.60 [ 54.47, 88.94] 0.58	AlAteeq et al, 2020	502			51.40 [ 43.15, 61.23] 0.59	Florin et al, 2020	1515		14.60 [ 1	12.66, 16.84] 0.5
Xiao et al, 2020	170	_	- 87.65 [ 55.50, 138.41]		Chew et al, 2020	906		7.	7.95 [ 6.25, 10.11] 0.58	Liu et al, 2021	1090			13.30 [ 11.17, 15.84] 0.59	Silva et al, 2020	806		46.41 [ 4	0.41, 53.30] 0.5
Liu et al, 2020	2126	-	0.92 [ 0.59, 1.44]		Mosolova et al, 2020	1090		6.	6.79 [ 5.36, 8.60] 0.58	Monterrosa-Castro et al, 2020	531			39.30 [ 33.02, 46.78] 0.59	Lu et al, 2020	965		34.40 [ 3	30.12, 39.29] 0.5
Shrestha et al, 2020	101	_	- 73.30 [ 47.17, 113.91]		Ozdin et al, 2020	343		28.	8.28 [ 22.36, 35.77] 0.58	Youssef et al, 2020	540			42.60 [ 35.92, 50.52] 0.59	Alamri et al, 2020	1597		16.40 [ 1	14.37, 18.72] 0.5
Shetchter et al, 2020	141	-	- 17.00 [ 10.96, 26.38]		Creese et al, 2020	3281		2.	2.20 [ 1.74, 2.78] 0.58	Tian et al, 2020	1060			15.00 [ 12.67, 17.75] 0.59	Ahmed et al, 2020	1074		29.00 [ 2	25.42, 33.09] 0.5
Smith et al, 2020	278	-	8.27 [ 5.40, 12.67]		Khanal et al, 2020	475		18.	8.30 [ 14.50, 23.09] 0.58	Zheng et al, 2020	617			32.60 [ 27.55, 38.58] 0.59	McCracken et al, 2020	1212	-	24.20 [ 2	21.22, 27.60] 0.5
Tan et al, 2020	673	-	3.27 [ 2.14, 5.00]		Zhang et al, 2020	927		8.	8.38 [ 6.64, 10.57] 0.58	Gorini et al, 2020	650			29.70 [ 25.10, 35.14] 0.59	Sahin et al, 2020	939		60.20 [ 5	52.83, 68.60] 0.5
Trumello et al, 2020	321	-	7.29 [ 4.79, 11.10]		Silva et al, 2020	348		28.	8.74 [ 22.79, 36.25] 0.58	Duncan et al, 2020	3971			3.60 [ 3.05, 4.25] 0.59	Barzilay et al, 2020	1350		22.00 [ 1	19.34, 25.02] 0.5
Crowe et al, 2020	109		- 67.90 [ 45.42, 101.51]	0.57	Prasad et al, 2020	347		69.	9.50 [ 55.30, 87.34] 0.58	Hummel et al, 2021	609			36.62 [ 31.05, 43.18] 0.59	Winkler et al, 2020	3306		7.79 [	6.86, 8.85] 0.5
Zheng et al, 2021	207	-	14.49 [ 9.84, 21.34]		Pieh et al, 2020	1006		8.	8.15 [ 6.50, 10.22] 0.58	Cheng et al, 2020	573			46.00 [ 39.03, 54.21] 0.59	Wang et al, 2020	951		51.60 [ 4	5.44, 58.60] 0.5
Roma et al, 2020	439	-	7.52 [ 5.27, 10.72]	0.57	Francisco et al, 2020	767		11.	1.47 [ 9.19, 14.32] 0.58	Bahadir-Yilmaz et al, 2020	1457			88.88 [ 75.49, 104.65] 0.59	Naser et al, 2020	1163		70.80 [ 6	62.39, 80.34] 0.5
Giannopoulou et al, 2020	442	-	7.47 [ 5.24, 10.65]	0.57	Yuan et al, 2020	3517		2.	2.30 [ 1.84, 2.87] 0.58	Cheng et al, 2020	623			60.00 [ 51.11, 70.43] 0.59	Pandey et al, 2020	1395		22.40 [ 1	19.75, 25.40] 0.5
Zhang et al, 2020	2143	-	1.59 [ 1.13, 2.23]		Wright et al, 2020	571		17.	7.30 [ 13.93, 21.49] 0.58	Cheng et al, 2020	647			61.00 [ 52.09, 71.44] 0.59	Jewell et al, 2020	1083		34.00 [ 2	29.98, 38.55] 0.5
Ni et al, 2020	214		22.00 [ 15.92, 30.40]	0.58	Shermna et al, 2020	591		16.	6.58 [ 13.35, 20.59] 0.58	Tiete et al, 2020	647			52.20 [ 44.74, 60.91] 0.59	Bendau et al, 2020	1328		24.90 [ 2	21.99, 28.20] 0.5
Omari et al, 2020	1057	11	40.40 [ 35.73. 45.68] 0	Gor	nzalez-Sanguino et al, 2020	3480		14.6	60 [ 13.29, 16.04] 0.59	Huang et al, 2020	7236			35.10 [ 33.45, 36.84] 0.	59				
Thomas et al, 2020	1039		55.70 [ 49.28, 62.95] 0	1.59	ser et al, 2020	1798			00 [ 52.81, 63.69] 0.59	Ferrucci et al, 2020	10025		•	21.00 [ 20.01, 22.03] 0.	59				
luang et al, 2020	1172		33.02 [ 29.24, 37.29] 0		o et al, 2020	2331			40 [ 23.14, 27.88] 0.59	Zhou et al, 2020	8079			37.40 [ 35.75, 39.12] 0.					
Cenat et al, 2021	1267	-	29.29 [ 25.95, 33.06] 0	J.J.	thod et al, 2020 billard et al, 2021	3984 2651			99 [ 11.84, 14.25] 0.59 10 [ 21.11, 25.28] 0.59	Ferrucci et al, 2020	10025			28.00 [ 26.81, 29.25] 0.					
Every-Palmer et al, 2020	2010		15.60 [ 13.83, 17.60] 0		et al, 2020	1970	Ter.		40 [ 39.70, 47.44] 0.59	Wang et al, 2020 Moghanibashi-Mansourieh et al, 2020	19372 10754			12.20 [ 11.69, 12.74] 0. 26.50 [ 25.39, 27.66] 0.					
3endau <i>et al,</i> 2020 Ni <i>et al,</i> 2020	1512 1577		24.50 [ 21.79, 27.55] 0 23.84 [ 21.23, 26.77] 0		Connor et al, 2020	3077			00 [ 19.26, 22.90] 0.59	Fisher et al, 2020	13829		- 5	20.50 [ 25.39, 27.66] 0. 21.00 [ 20.16, 21.88] 0.					
Cellini et al, 2020	1310		32.60 [ 29.04, 36.59] 0		ong et al, 2020	2872		24.3	35 [ 22.36, 26.52] 0.59	Zhou et al. 2020	11835		- T	34.40 [ 33.12, 35.73] 0.					
Rathod et al, 2020	3933		8.20 [ 7.32, 9.19] 0	14/	anigasooriya et al, 2020	2638		34.3	30 [ 31.65, 37.17] 0.59	Rossi et al, 2020	21342			21.25 [ 20.56, 21.96] 0.					
Cenat et al, 2021	1267		38.53 [ 34.41, 43.15] 0	1.50	billard et al, 2021	2651			70 [ 32.03, 37.59] 0.59	Wu et al, 2020	24789		T	51.60 [ 50.33, 52.90] 0.	59				
slam et al, 2020	1311			1.50	unmuller et al, 2020	4126			30 [ 16.91, 19.80] 0.59	Fancourt et al, 2020	36520		•	22.60 [ 22.05, 23.16] 0.	59				
Vang et al, 2020	1738		23.01 [ 20.58, 25.73] 0	0.55	nkler <i>et al,</i> 2020 nsel <i>et al,</i> 2021	3021 3549			63 [ 27.40, 32.04] 0.59 60 [ 24.69, 28.66] 0.59	Bareeqa et al, 2020	57311			21.80 [ 21.37, 22.24] 0.	59				
.ai et al, 2020 3anna et al, 2020	1257 1427		44.60 [ 39.91, 49.85] 0 33.70 [ 30.20, 37.61] 0		o et al, 2020	4827			60 [ 21.13, 24.18] 0.59	Overall				21.48 [ 18.68, 24.71]					
Kwong et al, 2020	2872		12.97 [ 11.63, 14.46] 0		nke et al, 2020	4335	- T		40 [ 27.54, 31.39] 0.59	Heterogeneity: T <sup>2</sup> = 0.86, I <sup>2</sup> = 99.76%, H									
Mrklas et al, 2020	1414		38.10 [ 34.22, 42.42] 0		klas et al, 2020	3951			70 [ 44.81, 50.77] 0.59	Test of $\theta_i = \theta_j$ : Q(171) = 25898.99, P = 0	0.00								
Hong et al, 2021	4692		8.10 [ 7.29, 9.00] 0		ire et al, 2021	8267		14.3	39 [ 13.53, 15.30] 0.59	Test of $\theta$ = 0: z = 42.98, P = 0.00	-								
Nang et al, 2020	1738		28.76 [ 25.92, 31.91] 0	100	tkamp et al, 2020	16245			20 [ 6.78, 7.64] 0.59		1/	/8 1	8	64					
echner et al, 2020	4276		9.31 [ 8.40, 10.32] 0		ang et al, 2020	4752		_		Random-effects REML model Sorted by: _meta_se									
Havaei et al, 2021	3676		11.10 [ 10.01, 12.30] 0		issad et al, 2020	5274 5683			40 [ 36.33, 40.59] 0.59 10 [ 48.51, 53.83] 0.59										
3endau <i>et al,</i> 2020 Ran <i>et al,</i> 2020	1804 1770		29.20 [ 26.38, 32.32] 0 31.90 [ 28.87, 35.25] 0		useppe et al, 2020 noming et al, 2020	8817			70 [ 19.66, 21.79] 0.59										
Ran et al, 2020 Fee et al, 2020	1879		28.80 [ 26.06, 31.82] 0		passo et al, 2021	5850	L Tel		20 [ 44.84, 49.69] 0.59										
Zhang et al, 2020	1563		44.70 [ 40.46, 49.39] 0		ng et al, 2020	60199	1	-	47 [ 92.64, 102.56] 0.59										
/arma et al, 2020	1653		59.00 [ 53.49, 65.08] 0		en et al, 2020	7772	•	26.9	90 [ 25.58, 28.28] 0.59										
Bendau et al, 2020	1855		36.40 [ 33.12, 40.01] 0		onso et al, 2020	9138	•		50 [ 21.42, 23.63] 0.59										
lohnson et al, 2020	1733	1	45.70 [ 41.58, 50.23] 0	0.59 Fran	anceschini et al, 2020	6439		52.6	60 [ 50.09, 55.24] 0.59							DOI: 10.5498/wjp.v12			


Figure 4 Forest plot of anxiety caused by severe acute respiratory syndrome coronavirus-2 forest plot.

# **Geographical location**

**SARS-CoV-2:** From Supplementary Figure 18-20, we can see that people in Canada are more likely to have anxiety (80.85%) and PTSD (83.99%) when they experience SARS-CoV-2, and they also showcase a relative high possibility of having depression (57.90%), while people in Palestine suffer from the highest prevalence of depression (88.38%). On the other hand, people in the United Kingdom have the lowest prevalence of depression (1.44%) among all the countries. And people in the United States and Australia have the lowest prevalence of PTSD (5.38%) and anxiety (3.78%) respectively.

Table	Table 12 Sensitivity analysis for anxiety and depression studies under severe acute respiratory syndrome coronavirus-2										
	Exposure	Outcome	Prevalence with 95%CI (before)	Prevalence with 95%CI (after)	P value						
(g)	SARS-CoV-2	Anxiety	21.48 (18.66-24.71)	25.82 (23.98-27.8)	< 0.05						
(h)	SARS-CoV-2	Depression	27.64 (24.59-31.06)	29.3 (26.98-31.81)	> 0.05						

SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; CI: Confidence interval.



DOI: 10.5498/wjp.v12.i5.739 Copyright ©The Author(s) 2022.

Figure 5 Forest plot of depression caused by Middle East respiratory syndrome.

**MERS:** A subgroup analysis was not conducted due to the studies taking place in South Korea only.

SARS-CoV: Supplementary Figure 21-23 indicate Taipei shows the highest prevalence of depression (38.36%) and anxiety (52.91%) during SARS-CoV. Moreover, people in Kaohsiung/Southern Taiwan also suffer from the highest prevalence of PTSD (45.52%) during SARS-CoV. This indicates that people in the Taiwan area may experience a serious mental health issue due to the outbreak of SARS-CoV. On the other hand, people in Toronto, Singapore and Beijing have the lowest prevalence of PTSD (13.01%), anxiety (17.5%) and depression (21.80%) respectively.

#### Publication bias and sensitivity analysis

The meta-analyses conducted indicate a high heterogeneity for depression, anxiety and PTSD. This could be due to differences in the reporting criteria and assessment tools used, geographical location and the difference in study designs, which had differing data collection time points. High heterogeneity could cause many studies to fall outside the 95%CI in the conventional funnel plot, which is based on the fixed effects model; therefore, we propose to use the funnel plot based on a random effects model. Both types of funnel plots were compared.

In the fixed effects model, the mean of the underlying model behind each study was fixed; therefore, the measure  $\tau^2$  for heterogeneity was 0. Since the random effects model assumes that the mean of each study comes from a normal distribution, the DerSimonian and Laird estimates  $\tau^2$  were calculated to show the heterogeneity between studies. The funnel plot based on the random effects model would include most of the studies and, therefore, make it easier to demonstrate publication bias. The pooled prevalence of the three mental health disorders and the 95%CI of the fixed (solid line) and random effects (dotted line) models were both plotted in Supplementary Figure 24 across all 3 pandemics.

When we looked at the funnel plots using the fixed effects model (solid line), most of the studies are located outside of the 95%CI. It is therefore difficult to find the sign of publication bias. They are masked by the widespread studies. By contrast, most of studies are well located within the 95%CI in the funnel plots using the random effects model (dotted line) except sub figs. Supplementary Figure 25A and B. Supplementary Figure 25C and D are typical examples. The large values of  $\tau^2$ , 1.1110 and 0.4574



Ko, CH       365       870 [6.05, 12.52]       2.89         Ko, CH       1107       2.00 [1.31, 3.05]       2.82         Lee, TMC       45       2.56       2.80         Lee, TMC       44       4.11       1.10 [16.54, 58.46]       2.10 [2.97, 34.38]       3.08         Dang, WM       3735       3.10 [2.50, 45.28]       2.80       3.06       2.20 [2.30, 27.68]       3.07         Lu, X       549       3.08       2.10 [2.97, 34.38]       3.08       2.20 [2.30, 27.68]       3.07         Lu, X       549       3.08       2.20 [1.30, 27.68]       3.07       1.10 [5.66, 24.36]       2.33         Su, TP       70       70       3.85 [2.37, 62.31]       2.76       2.80 [1.64, 31.22]       2.45 [2.86         Kwek, SK       63       11.10 [5.06, 24.36]       2.33       11.10 [5.06, 24.36]       2.33         Fang, Y       284       11.10 [5.06, 24.36]       2.33       11.10 [5.06, 24.36]       2.33         Shi, C       41       4.30 [1.13, 3.06]       2.56       2.56       2.56       2.56       2.56       2.56       2.56       2.56       2.56       2.56       2.57       2.56       2.80 [1.48, 35.97]       2.51       2.56       2.56       2.56	Study	Study Size					Prevalence with 95% CI					
Lee, TMC 45 Lee, TMC 26 Lee, TMC 34 Lee, TMC 41 Hawyluck, L 129 Dang, WM 3735 Dang, WM 2433 Lu, X 549 Su, TP 70 Lu, X 549 Su, TP 70 Lu, M 181 Kwek, SK 63 Fang, Y 284 Yp, KW 61 Chan, MH 181 Shi, C 41 Lam, MH 182 Shi, C 41 Lam, MH 182 Shi, Shi, C 41 Lam, MH 182 Shi, Shi, S	Ko, CH	365				8.70 [ 6.05,	12.52]	2.89				
Lee, TMC 28 Lee, TMC 34 Lee, TMC 41 Hawyluck, L 129 Dang, WM 3735 Dang, WM 2433 Leu, X 549 Su, TP 70 Lu, X 549 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yp, KW 61 Cheng, SK 180 Wu, KK 131 Lam, MH 181 Shi, C 41 Lam, Shi 181 Shi, C 41 Shi 22, C 72, C 74, 72, 82, 82 Shi 22, 255 Shi 24, 255	Ko, CH	1107				2.00 [ 1.31,	3.05]	2.82				
Lee, TMC $34$ Lee, TMC $41$ Hawryluck, L 129 Dang, WM 2433 Liu, X 549 Su, TP 70 Su, C 43 Su, C 41 Lam, MH 181 Hang, W 109 Huang, W 109 H	Lee, TMC	45		_		31.10 [ 16.54,	58.46]	2.55				
Lee, TMC 41 Hawryluck, L 129 Dang, WM 3735 Dang, WM 2433 Liu, X 549 Su, TP 70 Liu, X 549 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Ma, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, J.D 56 Wu, KK 131 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 105 Huang, J.D 56 Huang, J.D 56 Huang, J.D 56 Huang, J.D 56 Huang, J.D 58 Huang, J.D 56 Huang, J.D 58 Huang, J.D 58 Huang, J.D 56	Lee, TMC	26		_		34.60 [ 15.42,	77.63]	2.29				
Hawryluck, L 129 Dang, WM 3735 Dang, WM 2433 Liu, X 549 Su, TP 70 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, IW 90 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Cheng, X 109 Shi, C 41 Lam, MH 181 Shi, C 41 Shi, C 41 Shi, C 42 Shi, C 41 Shi, C 42 Shi, C 41 Shi, C 42 Shi, C 42 Shi, C 43 Shi, C 44 Shi, C 45 Shi, C 44 S	Lee, TMC	34			<b>—</b>	23.50 [ 10.64,	51.92]	2.32				
Dang, WM 3735 Dang, WM 2433 Liu, X 549 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, W 90 Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Hang, W 109 Huang, H 181 Huang, W 109 Huang, H 181 Huang, W 109 Huang, H 181 Huang, W 109 Huang, H 181 Huang, H 181 Huang	Lee, TMC	41				14.60 [ 6.14,	34.74]	2.21				
Dang, WM 2433 Liu, X 549 Su, TP 70 Liu, X 549 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Ma, IW 90 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Chen, R 116 Cheng, X 67 Huang, W 109 Huang, M 109 Huang,	Hawryluck, L	. 129			+=-	31.20 [ 21.50,	45.28]	2.88				
Liu, X 549 Su, TP 70 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, IW 90 Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Kwek, SK 64 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Hang, W 109 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 105 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 105 Huang, W 105 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 104 Huang, W 105 Huang, W 105 H	Dang, WM	3735				32.10 [ 29.97,	34.38]	3.08				
Su, TP 70 Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, W 90 Shi, C 43 Shi, C 41 Lam, MH 181 Hang, W 109 Huang, M 108 Huang, M 109 Huang, M 108 Huang, M 1	Dang, WM	2433				25.20 [ 23.00,	27.62]	3.07				
Su, TP 70 Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 MA, IW 90 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huan	Liu, X	549				22.80 [ 18.68,	27.83]	3.02				
Lam, MH 181 Kwek, SK 63 Fang, Y 284 Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, W 90 Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Hu 50 Yu, HYB 126 Lee, AM 63 Huang, W 109 Huang, Huang, Huang, Huang, Huang, Huang, Huang, Huang, Huang, Hua	Su, TP	70			+-	17.10 [ 9.18,	31.86]	2.56				
Kwek, SK       63         Fang, Y       284         Yip, KW       61         Cheng, SK       180         Wu, KK       131         Mak, IW       90         Shi, C       43         Shi, C       43         Shi, C       41         Lam, MH       181         Lam, MH       181         Huang, W       109         Huang, W       103         Lee, AM       33         Lee, AM       33         Lee, AM       33         Hoog, J.D.       56	Su, TP	70				38.50 [ 23.79,	62.31]	2.75				
Fang, Y284Yip, KW61Cheng, SK180Wu, KK131Mak, IW90Shi, C43Shi, C43Shi, C41Lam, MH181Shi, C41Lam, MH181Huang, W109Huang, W109Hu H50Yu, HYB126Lee, AM33Lee, AM63Hong, X67Hawryluck, L129Chang, W174Wang, J.D.58Wang, J.D.58Chang, W116Yip, KW61Wu, KK131Moldofsky, H22Wu, KK131Moldofsky, H22Vur, KK131Moldofsky, H22Overall2Heterogeneity: $r^2 = 0.49$ , $r^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 28321184312.6223.10 [18.14, 29.40]44.622.6023.10 [18.14, 29.40]44.70 [20.7] = 378.83, $P = 0.00$ 28283212844.70 [20.7] = 378.83, $P = 0.00$ 2 </td <td>Lam, MH</td> <td>181</td> <td></td> <td>-</td> <td>+</td> <td>16.60 [ 11.22,</td> <td>24.56]</td> <td>2.86</td>	Lam, MH	181		-	+	16.60 [ 11.22,	24.56]	2.86				
Yip, KW 61 Cheng, SK 180 Wu, KK 131 Mak, IW 90 Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Huang, W 109 Huang, W 109 Huang, M 108 Huang,	Kwek, SK	63			+	11.10 [ 5.06,	24.36]	2.33				
Cheng, SK 180 Wu, KK 131 Mak, IW 90 Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huan	Fang, Y	284		-	-	16.40 [ 11.98,	22.45]	2.94				
Wu, KK       131         Mak, IW       90         Shi, C       43         Shi, C       43         Shi, C       43         Shi, C       41         Lam, MH       181         Shi, C       41         Lam, MH       181         Huang, W       109         Huang, W       11.6         Yu, HYB       12.6         Lee, AM       63         Hong, X       67         Hawryluck, L       12.9         Chang, W       174         Wang, J.D.       58         Wu, KK       131 <tr< td=""><td>Yip, KW</td><td>61</td><td></td><td>_</td><td>+</td><td>14.70 [ 7.24,</td><td>29.86]</td><td>2.44</td></tr<>	Yip, KW	61		_	+	14.70 [ 7.24,	29.86]	2.44				
Mak, $ W  = 90$ Shi, C = 43 Shi, C = 43 Shi, C = 41 Lam, MH = 181 Shi, C = 41 Lam, MH = 181 Huang, W = 109 Huang, M = 116 Yu, HYB = 126 Lam, MH = 184 Lee, AM = 63 Hong, X = 67 Hawryluck, L = 129 Chang, W = 174 Wang, J.D. = 56 Wang, J.D. = 56 Wang, J.D. = 58 Chen, R = 116 Yu, KX = 131 Moldofsky, H = 22 <b>Overall</b> Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; $Z(37) = 378.83$ , $P = 0.00$ 2 = 8 = 32 = 128	Cheng, SK	180		-	-	25.80 [ 18.48,	36.03]	2.92				
Shi, C 43 Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chang, W 174 Wu, KK 131 Moldofsky, H 22 Overall Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; $Z = 25.49$ , $P = 0.00$ Z 8 3Z 128	Wu, KK	131		_	-	13.00 [ 7.81,	21.63]	2.72				
Shi, C 43 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chang, W 116 Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Typ, KW 61 Wu, KK 131 Meterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; $Z = 25.49$ , $P = 0.00$ Z = 8 $3Z$ $128A = 32$ $128A = 32$ $128A = 32$ $128$	Mak, IW	90		_	<b>—</b>	18.90 [ 11.15,	32.04]	2.69				
Shi, C 41 Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; $Q(37) = 378.83$ , $P = 0.00$ Test of $\theta = 0$ ; $z = 25.49$ , $P = 0.00$ z 8 32 128	Shi, C	43		_		28.96 [ 14.98,	55.97]	2.51				
Lam, MH 181 Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 Overall Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ ; Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ ; $z = 25.49$ , $P = 0.00$ $\frac{1}{2}$ 8 $32$ $128$ 44.70 [33.35, $59.92$ ] 2.95 5.36 [1.38, 20.86] 1.56 44.70 [33.35, $59.92$ ] 2.95 5.36 [1.38, 20.86] 1.56 44.70 [33.35, $59.92$ ] 2.95 6.69 [4.46, 16.92] 2.50 74.06 [4.46, 16.92] 2.50 74.07 [34.00, 161.34] 2.34 45.58 [27.76, 74.83] 2.73 93.80 [27.98, 56.62] 2.90 74.06 [40.74, 134.62] 2.60 93.80 [27.98, 56.62] 2.90 74.06 [40.74, 134.62] 2.60 93.80 [50.91, 128.34] 2.77 74.06 [40.74, 134.62] 2.60 93.80 [50.91, 128.34] 2.77 74.06 [40.74, 134.62] 2.59 23.81 [ 8.93, 63.51] 2.05 23.10 [18.14, 29.40] 43.46 [26.20, 72.10] 2.72 33.10 [18.14, 29.40] 43.46 [26.20, 72.10] 2.72 33.10 [18.14, 29.40]	Shi, C	43			<b></b>	40.02 [ 21.74,	73.66]	2.58				
Shi, C 41 Lam, MH 181 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chang, M 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ z 8 32 128 <b>Sol</b> (27) <b>Sol</b> (2	Shi, C	41				5.36 [ 1.38,	20.86]	1.56				
Lam, MH 181 Huang, W 109 Huang, W 109 Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ z 8 32 128 d 44.70 [ 33.35, 59.92] 2.95 8.69 [ 4.46, 16.92] 2.50 18.43 [ 11.36, 29.91] 2.75 22.24 [ 11.42, 43.31] 2.50 22.24 [ 11.42, 43.31] 2.50 22.49 [ 14.80, 34.17] 2.83 22.49 [ 14.80, 34.17] 2.83 45.58 [ 27.76, 74.83] 2.73 20.05 [ 11.03, 36.46] 2.60 $d 5 39.80 [ 27.98, 56.62] 2.90d 5 38.94 [ 55.38, 142.84] 2.76d 5 38.94 [ 5 38.94 [ 5 38.94 [ 5 38.94 [ 5 38.9$	Lam, MH	181			-	44.70 [ 33.35,	59.92]	2.95				
Huang, W 109 Huang, W 109 Hu A 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ Huang, W 109 Hawryluck, L 129 Chang, W 174 Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta_2 = 0$ : $z = 25.49$ , $P = 0.00$	Shi, C	41		-		5.36 [ 1.38,	20.86]	1.56				
Huang, W 109 Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ Hawryluck I 109 Huang, W 174 Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; Q(37) = 378.83, $P = 0.00$ Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; Q(37) = 378.83, $P = 0.00$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; Q(37) = 378.83, $P = 0.00$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = 0$ ; Q(37) = 378.83, $P = 0.00$ Heterogeneity: $r^2 = 10.49$ , $P = 10.00$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Heterogeneity: $r^2 = 10.49$ , $l^2 = 10.49$ ,	Lam, MH	181			-	44.70 [ 33.35,	59.92]	2.95				
Hu H 50 Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 8 32 128	Huang, W	109		_		8.69 [ 4.46,	16.92]	2.50				
Yu, HYB 126 Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 8 32 128	Huang, W	109		_	⊢	18.43 [ 11.36,	29.91]	2.75				
Lee, AM 33 Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ z 8 32 128	Hu H	50		-		22.24 [ 11.42,	43.31]	2.50				
Lee, AM 63 Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ Heterogeneity: $r^2 = 25.49$ , $P = 0.00$	Yu, HYB	126		-	_	22.49 [ 14.80,	34.17]	2.83				
Hong, X 67 Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ z 8 32 128	Lee, AM	33					161.34]	2.34				
Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ <b>a</b> 39.80 [ 27.98, 56.62] 2.90 <b>b</b> 39.80 [ 27.98, 56.62] 2.90 <b>c</b> 48.8.94 [ 55.38, 142.84] 2.76 <b>c</b> 74.06 [ 40.74, 134.62] 2.60 <b>b</b> 15.64 [ 7.70, 31.76] 2.44 <b>c</b> 80.83 [ 50.91, 128.34] 2.77 <b>v</b> 43.46 [ 26.20, 72.10] 2.72 <b>8</b> .91 [ 4.88, 16.25] 2.59 <b>23</b> .81 [ 8.93, 63.51] 2.05 <b>23</b> .10 [ 18.14, 29.40] <b>v</b> 43.46 [ 40.74, 134.62] 2.60 <b>v</b> 43.46 [ 26.20, 72.10] 2.72 <b>v</b> 43.46 [ 4.88, 16.25] 2.59 <b>v</b> 43.46 [ 4.88, 16.25] 2.59	Lee, AM	63				45.58 [ 27.76,	74.83]	2.73				
Hawryluck, L 129 Chang, W 174 Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ <b>A B B B B B B B B B B</b>	Hong, X	67		_	-	20.05 [ 11.03,	36.46]	2.60				
Wang, J.D. 56 Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $\tau^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 $3$ $3$ $3$ $2$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$	-	. 129				39.80 [ 27.98,	56.62]	2.90				
Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 8 32 128 15.64 [ 7.70, 31.76] 2.44 80.83 [ 50.91, 128.34] 2.77 43.46 [ 26.20, 72.10] 2.72 8.91 [ 4.88, 16.25] 2.59 23.81 [ 8.93, 63.51] 2.05 23.10 [ 18.14, 29.40]	Chang, W	174			_	- 88.94 [ 55.38,	142.84]	2.76				
Wang, J.D. 58 Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 8 32 128 15.64 [ 7.70, 31.76] 2.44 80.83 [ 50.91, 128.34] 2.77 43.46 [ 26.20, 72.10] 2.72 8.91 [ 4.88, 16.25] 2.59 23.81 [ 8.93, 63.51] 2.05 23.10 [ 18.14, 29.40]	-	56					-					
Chen, R 116 Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 $8 0.83 [50.91, 128.34] 2.77 43.46 [26.20, 72.10] 2.72 8.91 [4.88, 16.25] 2.59 23.81 [8.93, 63.51] 2.05 23.10 [18.14, 29.40] 2 3 3 2 3 3 3 3 3 3 3 3 3 3$					L _	-	-					
Yip, KW 61 Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $r^2 = 0.49$ , $l^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ $2$ $\frac{1}{2}$ $\frac{1}{8}$ $\frac{1}{32}$ $\frac{1}{128}$ $43.46$ [ 26.20, 72.10] 2.72 8.91 [ 4.88, 16.25] 2.59 23.81 [ 8.93, 63.51] 2.05 23.10 [ 18.14, 29.40]					_							
Wu, KK 131 Moldofsky, H 22 <b>Overall</b> Heterogeneity: $\tau^2 = 0.49$ , $I^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ $2 \frac{1}{2}$						-						
Moldofsky, H 22 <b>Overall</b> Heterogeneity: $\tau^2 = 0.49$ , $I^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_1 = \theta_1$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2 $3$ $3$ $3$ $2$ $3$ $3$ $3$ $2$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$ $3$				_			-					
Overall       23.10 [ 18.14, 29.40]         Heterogeneity: $\tau^2 = 0.49$ , $I^2 = 95.03\%$ , $H^2 = 20.14$ 23.10 [ 18.14, 29.40]         Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ 2         Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$ 2         2       8       32	,						-					
Heterogeneity: $\tau^2 = 0.49$ , $I^2 = 95.03\%$ , $H^2 = 20.14$ Test of $\theta_i = \theta_i$ : $Q(37) = 378.83$ , $P = 0.00$ Test of $\theta = 0$ : $z = 25.49$ , $P = 0.00$						-	-					
Test of $\theta_i = \theta_i$ : Q(37) = 378.83, $P = 0.00$ Test of $\theta = 0$ : z = 25.49, $P = 0.00$		$h^2 = 0.49$ $l^2 = 95.03\%$ $H^2 = 20.14$				20.10[10.14,	23.40]					
Test of $\theta = 0$ : $z = 25.49, P = 0.00$												
2 8 32 128												
	1651 01 0 = 0	. 2 - 20.49, F - 0.00		0	22	129						
			2	0	32	120						

DOI: 10.5498/wjp.v12.i5.739 Copyright ©The Author(s) 2022.

#### Figure 6 Forest plot of depression that is caused by severe acute respiratory syndrome coronavirus.

confirm the severe heterogeneity, and the random effects model we used addresses this problem well. We can therefore focus on the problem of publication bias.

Based on the 95%CI of the random effects model (dotted line), there is little sign of publication bias in Supplementary Figure 25C-F; the P values of Egger's test of 0.082, 0.589, 0.146 and 0.539 echo the findings (Table 7). In Supplementary Figure 25G-I, however, there is a sign of publication bias and the P values of the Egger's test are all less than 0.05, confirming the findings (Table 11).

Even if we used the funnel plot based on the random effects model, many studies in Supplementary Figure 25A and B still fall outside the 95%CI, meaning the random effects model cannot address the problem of heterogeneity well. Further investigation is required. The sign of publication



#### Delanerolle G et al. EPIC MERS\_SARS\_COVID-19 comparator

			Prevalence Weight	Wright et al, 2020 571	=	20.10 [ 16.38, 24.67] 0.84
Study	Study Size		with 95% CI (%)	Juan <i>et al</i> , 2020 456	+	29.60 [ 24.21, 36.19] 0.84
Yang et al, 2020	54		11.10 [ 4.75, 25.95] 0.59	Shermna et al, 2020 591	=	21.00 [ 17.23, 25.60] 0.84
Ma et al, 2020	34		24.00 [ 10.92, 52.73] 0.62	He et al, 2020 403		48.60 [ 39.98, 59.08] 0.84
Peng et al, 2020	139		86.63 [ 53.15, 141.19] 0.75	Bartoszek et al, 2020 471 Cai et al, 2020 1173		32.45 [ 26.76, 39.35] 0.84 10.10 [ 8.35, 12.21] 0.84
Saracoglu et al, 2020 Arac et al, 2020	208 100		- 89.90 [ 57.27, 141.13] 0.76 - 73.77 [ 47.25, 115.18] 0.76	Zhao <i>et al</i> , 2020 515		10.10 [ 8.35, 12.21] 0.84 29.70 [ 24.58, 35.88] 0.84
Arac et al, 2020	98		- 73.77 [47.25, 115.18] 0.76 29.70 [19.26, 45.81] 0.77	Sediri <i>et al</i> , 2020 751	Τ.	82.30 [ 68.24, 99.26] 0.84
Civantos et al, 2020	163		16.00 [ 10.53, 24.32] 0.77	Gorini et al, 2020 650		22.80 [ 18.98, 27.39] 0.84
Martinotti et al, 2020	119	-	28.56 [ 19.19, 42.51] 0.78	Ning et al, 2020 612		25.00 [ 20.82, 30.02] 0.84
Zheng et al, 2021	207		14.49 [ 9.84, 21.34] 0.78	Hazarika et al, 2021 541	=	32.00 [ 26.71, 38.34] 0.84
Crowe et al, 2020	109		57.80 [ 39.52, 84.53] 0.79	Azoulay et al, 2020 498		40.60 [ 33.95, 48.55] 0.84
Shah et al, 2020	207		15.90 [ 10.95, 23.08] 0.79	Fong et al, 2020 590	<b>#</b>	29.70 [ 24.89, 35.44] 0.84
Shah et al, 2020	207		15.90 [ 10.95, 23.08] 0.79	Creese et al, 2020 3281	•	4.10 [ 3.45, 4.87] 0.84
Than et al, 2020	173		20.20 [ 13.94, 29.28] 0.79	Yousseef et al, 2020 540		50.10 [ 42.32, 59.31] 0.84
Ni et al, 2020	214		19.20 [ 13.66, 26.98] 0.80	Cai et al, 2020 1173		14.30 [ 12.14, 16.84] 0.84
Suryavanshi et al, 2020	197		22.00 [ 15.70, 30.82] 0.80	Hummel et al, 2021 609 Tiete et al, 2020 647		55.38 [ 47.20, 64.97] 0.84 53.30 [ 45.67, 62.20] 0.84
Chew et al, 2021 Eweida et al, 2020	200 150		22.41 [ 16.07, 31.25] 0.80 62.70 [ 45.04, 87.29] 0.80	Sahin <i>et al</i> , 2020 939		77.60 [ 66.56, 90.47] 0.84
Smith et al, 2020	278		62.70 [ 45.04, 87.29] 0.80 15.87 [ 11.50, 21.89] 0.80	Liu <i>et al</i> , 2021 1090		18.40 [ 15.79, 21.45] 0.84
Mahamid et al, 2021	400		88.38 [ 65.09, 119.99] 0.81	Florin <i>et al</i> , 2020 1515		12.50 [ 10.73, 14.56] 0.84
Francisco et al, 2020	767	-	5.72 [ 4.22, 7.76] 0.81	Judith et al, 2020 695	_	59.50 [ 51.14, 69.23] 0.85
Pan et al, 2020	194	-	37.60 [ 28.12, 50.28] 0.81	Faulker et al, 2020 8425		2.07 [ 1.78, 2.40] 0.85
Khanal et al, 2020	475	-	13.50 [ 10.38, 17.56] 0.82	Kar et al, 2020 733		39.40 [ 33.97, 45.69] 0.85
Li et al, 2020	225	-	46.70 [ 35.94, 60.68] 0.82	Wang et al, 2020 1397	-	15.20 [ 13.13, 17.59] 0.85
Prasad et al, 2020	347	-8-	22.80 [ 17.74, 29.30] 0.82	Barzilay et al, 2020 1350		16.00 [ 13.83, 18.51] 0.85
Roma et al, 2020	439	-	17.82 [ 13.96, 22.75] 0.83	Creese et al, 2020 3281		5.90 [ 5.10, 6.82] 0.85
Mekonen et al, 2020	302	_ =	55.30 [ 44.08, 69.38] 0.83	Silva et al, 2020 806		60.43 [ 52.47, 69.59] 0.85
Garre-Olmo et al, 2021	692		12.70 [ 10.15, 15.88] 0.83	Idrissi <i>et al</i> , 2020 846 Tang <i>et al</i> , 2020 2501		35.60 [ 30.93, 40.98] 0.85 9.00 [ 7.85, 10.32] 0.85
Zheng et al, 2020 Ozdin et al, 2020	617 343	•	15.40 [ 12.38, 19.16] 0.83 37.85 [ 30.43, 47.08] 0.83	Jewell <i>et al</i> , 2020 1083		9.00 [ 7.85, 10.32] 0.85 29.00 [ 25.43, 33.07] 0.85
Tian et al, 2020	1060		8.40 [ 6.76, 10.44] 0.83	Lu <i>et al,</i> 2020 965	T	45.70 [ 40.26, 51.87] 0.85
Silva et al. 2020	348		40.81 [ 32.96, 50.54] 0.83	Cellini et al, 2020 1310		24.20 [ 21.33, 27.46] 0.85
Khanal et al, 2020	475		24.00 [ 19.44, 29.63] 0.83	Ni et al, 2020 1577		19.21 [ 16.95, 21.77] 0.85
He et al, 2020	374	-	58.60 [ 47.70, 71.99] 0.84	Duong et al, 2020 1385		23.50 [ 20.76, 26.61] 0.85
				Bendau et al, 2020 1328		25.30 [ 22.36, 28.63] 0.85
Thomas et al, 2020	1039		58.40 [ 51.62, 66.07] 0.85	Gao et al, 2020 4827		48.30 [ 45.65, 51.11] 0.86
McCracken et al, 2020	1212	•	30.00 [ 26.53, 33.92] 0.85	Capasso et al, 2021 5850	÷	29.60 [ 27.98, 31.31] 0.86
Omari et al, 2020	1057		57.00 [ 50.47, 64.38] 0.85	Giuseppe et al, 2020 5683	-	37.80 [ 35.83, 39.88] 0.86
Tee et al, 2020	1879		16.90 [ 14.98, 19.07] 0.85	Franceschini et al, 2020 6439	_   ■	67.90 [ 64.44, 71.55] 0.86
Bendau et al, 2020	1512		25.20 [ 22.44, 28.30] 0.85	Xiaoming <i>et al</i> , 2020 8817	<b>_</b>	20.20 [ 19.18, 21.28] 0.86
Fountoulakis et al, 2021	3399		9.31 [ 8.29, 10.45] 0.85	Alonso et al, 2020 9138	Π_	28.10 [ 26.85, 29.41] 0.86
Pandey et al, 2020 Mrklas et al, 2020	1395 1414		30.50 [ 27.21, 34.18] 0.85 32.10 [ 28.71, 35.89] 0.85	Chen et al, 2020         7772           Zhou et al, 2020         8079		42.89 [ 41.01, 44.86] 0.86 43.70 [ 41.82, 45.66] 0.86
Mrklas et al, 2020	1414		32.10 [ 28.71, 35.89] 0.85 32.10 [ 28.71, 35.89] 0.85	Wang et al, 2020 19372		43.70 [ 41.82, 45.66] 0.86 12.20 [ 11.69, 12.74] 0.86
Lai et al, 2020	1257	E E E	50.40 [ 45.12, 56.29] 0.85	Mamun <i>et al,</i> 2021 10067	_	33.30 [ 31.95, 34.71] 0.86
Alamri et al, 2020	1597		28.90 [ 25.94, 32.20] 0.85	Fisher <i>et al</i> , 2020 13829		27.60 [ 26.59, 28.65] 0.86
Brailovskaia et al, 2021	1931		22.94 [ 20.63, 25.51] 0.85	Song et al, 2020 14825		25.20 [ 24.28, 26.15] 0.86
Banna et al, 2020	1427		57.90 [ 52.12, 64.32] 0.85	Fancourt et al, 2020 36520		25.10 [ 24.51, 25.70] 0.86
Varma et al, 2020	1653		34.90 [ 31.54, 38.61] 0.85	Jiang et al, 2020 60199		80.02 [ 78.44, 81.63] 0.86
Bendau et al, 2020	1804		30.50 [ 27.59, 33.72] 0.85	Wu et al, 2020 247896		47.50 [ 47.13, 47.88] 0.86
Zhang et al, 2020	1563		50.70 [ 45.91, 55.99] 0.85	Overall		27.64 [ 24.59, 31.06]
Guo et al, 2020	2331		21.30 [ 19.29, 23.52] 0.85	Heterogeneity: r <sup>2</sup> = 0.41, I <sup>2</sup> = 99.69%, H <sup>2</sup>	<sup>2</sup> = 325.81	
Hong et al, 2021	4692		9.40 [ 8.52, 10.37] 0.85	Test of $\theta_i = \theta_j$ : Q(119) = 24186.32, <b>P</b> = 0.	.00	
Fukase et al, 2021	2708		18.35 [ 16.65, 20.23] 0.85	Test of $\theta$ = 0: z = 55.72, <b>P</b> = 0.00	· · · · · · · · · · · · · · · · · · ·	
Bendau et al, 2020 Every-Palmer et al, 2020	1855 2010		32.70 [ 29.68, 36.03] 0.85 30.30 [ 27.55, 33.32] 0.85		2 8 32	128
Johnson et al. 2020	1733	E State Sta	56.30 [ 51.20, 61.91] 0.85	Random-effects REML model Sorted by: _meta_se		
Kwong et al, 2020	2872		18.14 [ 16.50, 19.95] 0.85			
Ran et al, 2020	1770		47.10 [ 42.90, 51.71] 0.85			
Peng et al, 2020	2098		35.80 [ 32.74, 39.14] 0.85			
Kwong et al, 2020	2872		24.35 [ 22.36, 26.52] 0.85			
O'Connor et al, 2020	3077		23.70 [ 21.81, 25.75] 0.85			
O'Connor et al, 2020	3077		24.30 [ 22.38, 26.39] 0.85			
Wanigasooriya et al, 202			31.20 [ 28.73, 33.88] 0.85			
Darly et al, 2020	5428	<b>—</b>	14.20 [ 13.16, 15.32] 0.85			
Cansel et al, 2021	3549		34.30 [ 32.00, 36.76] 0.85			
Benke et al, 2020	4335		31.10 [ 29.16, 33.17] 0.86			
Mrklas et al, 2020	3951		43.60 [ 40.94, 46.43] 0.86			
Traunmuller et al, 2020 Huang et al, 2020	4126 7236		45.65 [ 42.94, 48.53] 0.86 20.10 [ 18.98, 21.29] 0.86			
Wang et al, 2020	4752	-	51.50 [ 48.65, 54.51] 0.86			
				<b>DOI:</b> 10.54	498/wjp.v12.i5.739 Copyrigh	t ©The Author(s) 2022.

Figure 7 Forest plot of depression caused by severe acute respiratory syndrome coronavirus-2.

bias is not clear; the *P* values of Egger's test are 0.085 and 0.000 respectively for Supplementary Figure 25A and B.

To reduce the unclear impact of studies that fall outside the 95%CI of random effects model in Supplementary Figure 25A and B, further sensitivity analyses, by removing the studies external to the 95%CI range, was demonstrated in Table 12.

The prevalence of anxiety and depression under SARS-COV-2 (Supplementary Figure 25A and B) are significantly higher after removing the studies external to the 95%CI, with the result changing from 21.44% (18.69-24.61) to 25.54% (23.28-28.02) and 27.68% (24.67-31.06) to 29.7% (27.25-32.39) respectively. It means that factors associated with heterogeneity, say, the design, population and quality of those studies, may have some impact on the conclusion and a further inspection of the study quality and other factors are needed.

Baishidena® WJP | https://www.wjgnet.com

Study	Study size							Prevalen with 95%		Weight (%)	
Shermna, A.C	591		_	-				5.38 [ 3.76,	7.69]	5.03	
Civantos, A.M	163							- 73.70 [ 52.00,	104.45]	5.04	
Peng, M	139					-	$\vdash$	41.24 [ 29.42,	57.81]	5.06	
Li, X	225							31.60 [ 23.86,	41.85]	5.15	
Liang, L	584				-			14.40 [ 11.43,	18.14]	5.21	
Zhang, H	642				-	┠		20.87 [ 17.25,	25.25]	5.26	
Kar, N	733					-		34.10 [ 29.27,	39.73]	5.29	
Greenberg, N	709						ŀ	40.00 [ 34.42,	46.49]	5.30	
Johnson, S.U	1733			-	ŀ			11.70 [ 10.11,	13.55]	5.30	
Peng, M	2098							13.25 [ 11.68,	15.03]	5.31	
Li, Q	1109							67.09 [ 59.19,	76.04]	5.32	
Riello, M	1071							39.00 [ 34.49,	44.10]	5.32	
Tee, M.L	1879							31.20 [ 28.30,	34.40]	5.33	
Wanigasooriya, K	2638					÷		24.50 [ 22.42,	26.77]	5.34	
Bonsaken, T	4527							18.40 [ 17.07,	19.84]	5.34	
Nkire, N	8267							83.99 [ 79.19,	89.08]	5.35	
Song, X	14825							9.10 [ 8.60,	9.62]	5.35	
Alonso, J	9138							22.20 [ 21.13,	23.32]	5.35	
Salehi, M	19428							18.00 [ 17.35,	18.67]	5.35	
Overall								25.03 [ 18.15,	34.51]		
Heterogeneity: T <sup>2</sup>	= 0.50, I <sup>2</sup> = 99	.58%, H <sup>2</sup> = 236.90						-			
Test of $\theta_i = \theta_j$ : Q(	18) = 3887.86,	P = 0.00									
Test of $\theta$ = 0: z =											
			4	8	16	32	64	-			
Random-effects RE Sorted by: _meta_s					- 100			• • • • • • • •			
				1001: 10	.5498/	wjp.v12	2.15.739	Copyright ©Th	e Autnor	(s) 2022.	

Figure 8 Forest plot of post-traumatic stress disorder that is caused by Middle East respiratory syndrome.

# DISCUSSION

The prevalence of anxiety, depression and PTSD was common across HCWs, patients and the general public. It could be argued HCWs experience psychological burden more profoundly than patients and the general public given that the exposure to negative thoughts would be higher within their work environment. Patients equally could experience a high psychological burden with the exacerbation of their conditions due to a number of factors such as isolation. The general public could equally experience a decline in their mental health due to the lockdown situation in some parts of the world more extensively than others, especially with SARS-CoV-2 as a number of national level lock-downs were imposed in different countries.

The incidence of anxiety across all groups during SARS-CoV-2 (33.16%) was higher in comparison to MERS (17.35%) and SARS-CoV (25.2%). MERS and SARS-CoV-2 demonstrated higher depressive symptoms, at 33.65% and 31.35% respectively, in comparison to SARS-CoV, which reported 23.1%. PTSD was much higher during MERS (35.9%) than SARS-CoV-2 (25.03%) and SARS-CoV (18.2%).

The prevalence of PTSD among HCWs during MERS was 49.87%. The highest prevalence of anxiety for HCWs was during SARS-CoV at 98.44%. Among HCWs, the highest reported prevalence thus far during SARS-CoV-2 appear to be depression and insomnia, at 37.97% and 35.16% respectively. The identified prevalence rates could be influenced directly and indirectly by stigmatisation being an attributor. Stigmatisation within this context could include social processes to discriminate or separate the usual life changes and opportunities. This issue could present a significant barrier in managing access to equitable and quality services. Individual or social construct based beliefs and behaviours could promote social discrimination and moral discredit that may aggravate mental health implications to worsen health outcomes[27]. Interestingly, Dye and colleagues indicated HCWs were unlikely to follow social distancing protocols compared to non-HCWs. This could be associated with bullying as



Study	Study Size		Prevalen with 95%		Weight (%)	Lin <i>et al,</i> 2007 Wu <i>et al,</i> 2005	83 131			-		19.30 [ 11.19, 12.00 [ 7.08,		
Su et al, 2007	70		1.00 [ 0.09,	10 531	0.52	McAlonan et al, 2007	71					26.77 [ 15.83,		
Chen et al. 2005	42		2.00 [ 0.23,			Chen et al, 2005	65			_ =		31.35 [ 18.56,		1.71
Lee et al, 2005	42		3.80 [ 0.51,	-		Maunder et al, 2006 Kwek et al, 2006	182 63			•		8.40 [ 4.98, 41.70 [ 25.27,		
Lee et al, 2006	41					Su ot al, 2007	70					32.80 [ 19.91,		1.73
			2.40 [ 0.32,	17.73]		Hong et al, 2009	67			- 17a	-	62.85 [ 38.29,		
Tham <i>et al</i> , 2004	38		4.04 [ 0.80,	20.31]		Gao et al, 2006	67				-	55.20 [ 34.11,	-	
Moldofsky et al, 201			9.50 [ 2.21,			Gao et al, 2006	67			-	F.	46.20 [ 28.58,	74.68]	1.74
Lee et al, 2006	34		5.90 [ 1.42,	-		Wu et al, 2005	131			-		15.00 [ 9.29,	24.23]	1.74
Chen et al, 2005	21		10.00 [ 2.40,			Hong et al, 2009	68			-	F	44.10 [ 27.32,	71.18]	1.74
Lancee et al, 2008	133		1.50 [ 0.37,		0.98	Hong et al, 2009	70			-	-	40.00 [ 24.80,	64.53]	1.74
Tham et al, 2004	38		10.00 [ 3.47,			Xu et al, 2004	89			-		25.80 [ 16.05,	-	
Chen et al, 2005	21	+=-	34.81 [ 14.18,			Mak et al, 2009	90			- <b>F</b> .	_	25.60 [ 15.95,		
Su et al, 2007	32		18.80 [ 7.75,	45.63]	1.40	Liang et al, 2004	90					67.80 [ 43.57,		1.77
Sim et al, 2004	47		12.80 [ 5.44,	30.12]	1.42	Xu et al, 2004 Xu et al, 2005	89 93				-	63.75 [ 41.38, 38.10 [ 25.07,	-	
Sim et al, 2004	47		13.37 [ 5.77,	30.97]	1.44	Mak et al, 2009	93 90					47.80 [ 31.61,		1.79
Wu et al, 2005	131	-=-	5.00 [ 2.28,	10.97]	1.48	Sun et al, 2005	114					30.70 [ 20.62,		
Wu et al, 2005	131		5.57 [ 2.64,	11.75]	1.52	Fang et al, 2004	284					9.79 [ 6.62,		1.80
McAlonan et al, 200	7 113		6.80 [ 3.27,	14.14]	1.53	Hawryluck et al, 2004	129			- <b>-</b>		27.20 [ 18.46,		
Lee et al, 2006	45	-#-	20.00 [ 9.63,	41.52]	1.53	Hawryluck et al, 2004	129			-		28.90 [ 19.75,	42.29]	1.81
Wu et al, 2005	131		6.00 [ 2.92,	12.34]	1.54	Xu et al, 2005	114					55.10 [ 38.10,	79.70]	1.82
Maunder et al, 2006	82		11.13 [ 5.59,	22.15]	1.57	Lam et al, 2009	181			-		23.20 [ 16.43,	32.76]	1.83
Wu et al, 2005	131		6.77 [ 3.42,	13.38]	1.58	Reynolds et al, 2008	269					22.40 [ 16.82,	29.84]	1.86
Chen et al. 2005	65		17.00 [ 8.90,	32.47]	1.61	Lau et al, 2006	407					13.30 [ 9.99,		1.86
Shan et al, 2004	87		- 87.50 [ 46.35,	-	1.62	Wu et al, 2009	549			<b>-</b>		10.00 [ 7.57,	-	1.87
Wu et al, 2005	131		8.00 [ 4.26,	-		Lau et al, 2006 Maunder et al, 2006	411 505					18.00 [ 14.00,		1.88
Yip et al, 2015	61		19.70 [ 10.48,	-		Maunder et al, 2006 Maunder et al, 2006	505					14.01 [ 10.90, 13.80 [ 10.91,		1.89
Yip et al, 2015	61		19.70 [ 10.48,	-		Reynolds et al, 2008	757					11.80 [ 9.46,	-	1.89
Tham <i>et al</i> , 2004	58		21.20 [ 11.29,	-		Chong et al, 2004	1257			7.1		67.25 [ 59.78,		1.93
Tham et al, 2004	58		22.54 [ 12.17,	-		Overall						18.20 [ 14.94,		
Wu et al, 2005	131		9.00 [ 4.95,				2, I <sup>2</sup> = 91.37%, H <sup>2</sup> = 11.59			Ť		10.201		
						Test of $\theta_i = \theta_i$ : Q(63) =								
Wu et al, 2005	131		9.00 [ 4.95,			Test of 0 = 0: z = 28.78								
Wu et al, 2005	131		10.00 [ 5.65,					1/8 1		8 6	\$4			
Lin et al, 2007	83		19.30 [ 11.19,	-		Random-effects REML n	nodel							
Wu et al, 2005	131		12.00 [ 7.08,	20.33]	1.71	Sorted by: _meta_se	<b>DOI:</b> 1	0.5498/wjp.v	/12.i5	.739 <b>C</b>	ору	right ©The	Author(	s) 2022

Figure 9 Forest plot of post-traumatic stress disorder that is caused by severe acute respiratory syndrome coronavirus.

demonstrated by Dye et al<sup>[27]</sup> Verbal and physical violence was also associated with bullying or harassment scenarios in comparison to MERS or SARS-CoV. This could be further purported with an influx of patients and workload that exacerbates fatigue and insomnia. This finding is consistent with MERS; therefore, it likely to occur with SARS-CoV-2.

Our results indicated age appear to play a role in mental illness manifestations during SARS-CoV-2, although there was insufficient data during MERS and SARS-CoV to conduct a comparative analysis. The pooled prevalence for ages between 20-29 years appear to demonstrate PTSD at 49.7% during MERS and 32.4% in SARS-CoV-2. Other mental illnesses during SARS-CoV-2 appear to be associated with 10 to 19 years of age with a significant prevalence of anxiety of 35.84% and insomnia (23.3%). In addition, depression was reported at 40.94% within the 30-39 age group.

The indirect influence of SARS-CoV-2 is widespread, especially among young people under 40 years old. For children and teenagers, the social isolation and loneliness of being unable to meet with friends will increase the anxiety. Students worry that the epidemic would limit their future choices and future education, employment and housing. Young workers have a higher rate of unemployment because of their immature skills. During MER-CoV, suicidality was reported at 16.62% with a 95% CI of 10.73-25.75, although the age range associated was non-specific.

Studies relating to SARS-CoV and MERs-COV are limited by several aspects, including the geographical constraints and sample sizes. The majority of studies were published in languages other than English. Psychological symptomatologies associated with depression, anxiety, distress, insomnia and fatigue, as well as comorbidities such as PTSD and neuro-psychiatric syndromes such as psychosis, have been reported in patients and HCWs more during the SARS-CoV-2 pandemic[28,29] which could be due to the scope and scale of the incidence and high transmission rates. The effects of mass lockdowns, economic downturns and mass uncertainty and fear within the general population are harder to characterise and assess, but early evidence suggests that rates of mental health disorders within the population will be higher during and following the pandemic[30,31]. More significant findings of severe psychological disorders including post-traumatic stress disorder and suicidal ideation amongst health care workers have been reported at levels greater than or expected to be seen in military veterans[32] or amongst victims of natural disasters[33]. Within the three groups there is likely to be variations in the levels of mental health disorders based on age, race and socio-economic status due to differences in the risk of mortality[34,35].

Non-specific use of MH interventions to support HCPs during each of the coronavirus disease outbreaks demonstrate the lack of preparedness global healthcare systems appeared to have had. Thereby, the ongoing SARS-CoV-2 will continue to impact their MH and overall well-being due to the lack of protective factors and assessments to identify specific risk factors. The available evidence demonstrates safeguarding measures should be considered by healthcare systems to better strategize

Study	Study size						Prevalen with 95%	Weight (%)		
Shermna, A.C	591			H				5.38 [ 3.76,	7.69]	5.03
Civantos, A.M	163							- 73.70 [ 52.00,	104.45]	5.04
Peng, M	139					-	H	41.24 [ 29.42,	57.81]	5.06
Li, X	225							31.60 [ 23.86,	41.85]	5.15
Liang, L	584				-			14.40 [ 11.43,	18.14]	5.21
Zhang, H	642				-	H		20.87 [ 17.25,	25.25]	5.26
Kar, N	733					-		34.10 [ 29.27,	39.73]	5.29
Greenberg, N	709					-	-	40.00 [ 34.42,	46.49]	5.30
Johnson, S.U	1733			-	ŀ			11.70 [ 10.11,	13.55]	5.30
Peng, M	2098							13.25 [ 11.68,	15.03]	5.31
Li, Q	1109							67.09 [ 59.19,	76.04]	5.32
Riello, M	1071							39.00 [ 34.49,	44.10]	5.32
Tee, M.L	1879							31.20 [ 28.30,	34.40]	5.33
Wanigasooriya, K	2638				1	÷		24.50 [ 22.42,	26.77]	5.34
Bonsaken, T	4527							18.40 [ 17.07,	19.84]	5.34
Nkire, N	8267							83.99 [ 79.19,	89.08]	5.35
Song, X	14825							9.10 [ 8.60,	9.62]	5.35
Alonso, J	9138							22.20 [ 21.13,	23.32]	5.35
Salehi, M	19428							18.00 [ 17.35,	18.67]	5.35
Overall								25.03 [ 18.15,	34.51]	
Heterogeneity: $\tau^2$	= 0.50, I <sup>2</sup> = 99	0.58%, H <sup>2</sup> = 236	5.90							
Test of $\theta_i = \theta_j$ : Q(	18) = 3887.86	<i>P</i> = 0.00								
Test of $\theta$ = 0: z =	19.63, P = 0.0	0								
			4	8	16	32	64	-		
Random-effects RE Sorted by: _meta_s			<b>DOI:</b> 10.	5498/v	/in.v1	2.i5.73	9 <b>Con</b>	<b>yright</b> ©The J	Author(s	) 2022.

DOI: 10.5498/wjp.v12.i5.739 Copyright ©The Author(s) 2022.

Figure 10 Forest plot of post-traumatic stress disorder caused by severe acute respiratory syndrome coronavirus-2. Cl: Confidence interval.

both collegial support and control steps to support all HCPs.

#### Limitations

Several factors, including communication and country, as well as regional directives and their differences, were paramount to the inclusion and exclusion of the evidence within this study. All 3 cohorts included within this study reported their mental health impact differently. Multiple mental health assessments were used; thus, cut-off scores were used to better evaluate and inform the statistical analysis conducted. Unified approaches for the assessment of pandemic-specific or related mental health among HCPs, patients and the public should be considered in the future. This is another factor that led to the observations of high variation in outcomes and risks to medium- to long-term mental health impact.

# CONCLUSION

As vaccines are rolled out globally, it is hoped that pressures on acute medical services due to the SARS-CoV-2 will slowly improve. The aim of this study is to understand and build on our knowledge of the viruses' impact on mental health, both previously and now, so that we may better manage and prepare to deal with the hidden consequences of this and any future outbreaks. Whilst there are cultural, economic and environmental differences between the countries affected in each pandemic, drawing similarities between the lasting effects on mental health will be important in highlighting where resources and support are needed as we contemplate our recovery-physically, mentally and socially-from this pandemic. The mortality impact of seasonal influenza and a pandemic on the mental health of the general public, patients and HCPs vary.

This study analysed the prevalence of mental health outcomes during the MERS, SARS-CoV and SARS-CoV-2 across multiple cohorts. In terms of mental illness like anxiety, depression and PTSD, the prevalence of depression (33.65% with 95%CI: 22.02-51.42) and PTSD (35.97% with 95%CI: 29.6-43.72) is higher during MERS, while the prevalence of anxiety (33.16% with 95%CI: 25.99-34.5) is higher during



SARS-CoV-2. Patients and HCWs are the first and second most likely groups to suffer from mental health problems. Young people are more likely to be caught up in depressive and anxiety emotions than older people.

Developing evidence-based and cohort-specific MH interventions could be a useful way to optimise MH support. HCPs in particular may benefit from this as it could promote better well-being for staff, increasing the efficiency within the work environment.

# ARTICLE HIGHLIGHTS

### Research background

The severe acute respiratory syndrome (SARS) virus has been present for centuries in different forms. Whilst civilisation has evolved, so has the virus, including its' ability to transmit. Thus, the comparison of the three most recent severe acute respiratory syndrome coronavirus (SARS-CoV) viruses in terms of the mental health implications infused to patients, healthcare professionals (HCPs) and patients is an important facet both clinically and scientifically. As a result, our study explores an important component that hasn't been addressed from a potential disease sequalae perspective.

### Research motivation

Our motivation was to demonstrate the trends associated with the mental health prevalence in terms of specific conditions due to the last three virulent strands of SARS-CoV across patient, HCPs and the general public. The specified cohorts have specific behavioural patterns and differing levels of exposure to the virus, thus the risk of infection varies that influences the mental health impact. This would aid in assessing the true mental health impact that health care systems require to support those needing mental health support. The comparison also allows us to predict the trends in mental health impact due to infectious transmissions which ultimately should be addressed as a public health hazard, globally.

### Research objectives

The study has three primary aims of identifying and reporting: (1) Mental health conditions commonly observed across all three pandemics; (2) Impact of mental health outcomes across patients, the general public and HCPs associated with all 3 pandemics; and (3) The prevalence of the mental health impact and clinical epidemiological significance.

# Research methods

A systematic methodology was developed and published on PROSPERO (CRD42021228697). The databases PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of Controlled Trials were used as part of the data extraction process, and publications from January 1, 1990 to August 1, 2021 were searched. MeSH terms and keywords used included Mood disorders, PTSD, Anxiety, Depression, Psychological stress, Psychosis, Bipolar, Mental Health, Unipolar, Self-harm, BAME, Psychiatry disorders and Psychological distress. The terms were expanded with a 'snowballing' method. Cox-regression and the Monte-Carlo simulation method was used in addition to P and Egger's tests to determine heterogeneity and publication bias.

#### **Research results**

The results indicated that there is a mental health impact observed among patients, HCPs and the general public at varying levels. This study analysed the prevalence of some mental health outcomes to the outbreaks of Middle East respiratory syndrome (MERS), SARS-CoV and SARS-CoV-2 and compared the prevalence of the participants and the prevalence of different occupational groups and age groups. In terms of mental illness like anxiety, depression and post-traumatic stress disorder (PTSD), the prevalence of depression [33.65% with 95% confidence interval (CI): 22.02-51.42] and PTSD (35.97% with 95% CI: 29.6-43.72) is higher during MERS, while the prevalence of anxiety (33.16% with 95% CI: 25.99-34.5) is higher during SARS-CoV-2. Patients and healthcare workers are the first and second most likely groups to suffer from mental health problems. Young people are more likely to be caught up in depressive and anxiety emotions than older people.

#### Research conclusions

Developing evidence-based and cohort-specific mental health (MH) interventions could be a useful way to optimise MH support. HCPs in particular may benefit from this as it could promote better well-being for staff, increasing the efficiency within the work environment. As vaccines are rolled out globally, it is hoped that pressures on acute medical services due to the SARS-CoV-2 will slowly improve. The aim of this study is to understand and build on our knowledge of the viruses' impact on mental health, both previously and now, so that we may better manage and prepare to deal with the hidden consequences of this and any future outbreaks. Whilst there are cultural, economic and environmental differences between the countries affected in each pandemic, drawing similarities between the lasting effects on



mental health will be important in highlighting where resources and support are needed as we contemplate our recovery-physically, mentally and socially-from this pandemic. The mortality impact of seasonal influenza and a pandemic on the mental health of the general public, patients and HCPs vary.

#### Research perspectives

Studies relating to SARS-CoV and MERS-CoV are limited by several aspects, including the geographical constraints and sample sizes. The majority of studies were published in languages other than English. Psychological symptomatologies associated with depression, anxiety, distress, insomnia and fatigue, as well as comorbidities such as PTSD and neuro-psychiatric syndromes such as psychosis, have been reported in patients and HCWs more during the SARS-CoV-2 pandemic which could be due to the scope and scale of the incidence and high transmission rates. The effects of mass lock-downs, economic downturns and mass uncertainty and fear within the general population are harder to characterise and assess, but early evidence suggests that rates of mental health disorders within the population will be higher during and following the pandemic. We need more comprehensive and longitudinal studies to be conducted to determine the mental health impact in multiple populations globally. This would also aid us to develop better pandemic preparedness frameworks and policies within healthcare systems.

# ACKNOWLEDGEMENTS

The authors acknowledge the following: Mr Tony Thayanandan, Associate Prof Steven Wai Ho Chau, Dr Sandra Chan, Dr Sheena Au-Yeung, Prof David Kingdon, Miss Natasha Sandle, Associate Prof Oscar Wong, Dr Evelyn Wong and Dr Li Yee Ting for contributions to the SARS-CoV and SARS-CoV-2 datasets that have been peer reviewed and published already. This paper is part of the multifaceted EPIC project that is sponsored by Southern Health NHS Foundation Trust and a collaboration between the University of Oxford, The Alan Turing Institute, Southern University of Science and Technology, China, University College London and University College London Hospitals NHS Foundation Trust.

# FOOTNOTES

Author contributions: Delanerolle G and Phiri P developed the systematic review protocol and embedded this within the EPIC project's evidence synthesis phase; Delanerolle G and Goodison W wrote the first draft of the manuscript; The statistical analysis plan was developed by Delanerolle G and was conducted by Shi JQ, Yeng X and Zeng Y; The data was critically appraised by Shetty A, Phiri P, Zeng Y, Yeng X, Shi JQ, Goodison W, Ramakrishnan R, Ranaweera S and Raymont V; The SARS-CoV data was extracted by Chau SWH and his team; The SARS-CoV-2 data was extracted by Phiri P/Delanerolle G and their team; Yeng X and Zeng Y extracted the MERS dataset which was reviewed by Delanerolle G, Phiri P, Shetty S, Shi JQ and Shetty A; Yeng X, Zeng Y and Shi JQ conducted the analysis; Shetty S designed and developed the original illustration; Delanerolle G, Phiri P, Shetty A, Zeng Y, Yeng X, Shetty S, Shi JQ, Goodison W, Ramakrishnan R, Elliot K, Ranaweera S and Raymont V critically appraised and finalised the manuscript; All authors approved the final version of the manuscript.

Supported by Southern Health NHS Foundation Trust.

Conflict-of-interest statement: Dr Phiri has received research grant from Novo Nordisk, and other, educational from Queen Mary University of London, other from John Wiley & Sons, other from Otsuka, outside the submitted work. Dr Rathod reports other from Janssen, Boehringer outside the submitted work. All other authors report no conflict of interest. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or the Academic institutions. The study sponsor had no further role in the study design, data collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the paper for publication.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: United Kingdom

**ORCID number:** Gayathri Delanerolle 0000-0002-9628-9245; Yutian Zeng 0000-0002-9902-0137; Jian-Qing Shi 0000-0002-2924-1137; Xuzhi Yeng 0000-0003-0909-8238; Will Goodison 0000-0002-4109-9049; Ashish Shetty 0000-0002-7441-6936;



Suchith Shetty 0000-0001-5541-0953; Nyla Haque 0000-0002-9127-110X; Kathryn Elliot 0000-0002-4483-1186; Sandali Ranaweera 0000-0001-7147-915X; Rema Ramakrishnan 0000-0002-6784-8319; Vanessa Raymont 0000-0001-8238-4279; Shanaya Rathod 0000-0001-5126-3503; Peter Phiri 0000-0001-9950-3254.

Corresponding Author's Membership in Professional Societies: Nursing and Midwifery Council (NMC), No. 9811393.

S-Editor: Fan IR L-Editor: A P-Editor: Yu HG

# REFERENCES

- National Institute of Allergy and Infectious Diseases (NIAID). Coronaviruses [Internet]. [cited 23 December 2021]. 1 Available from: https://www.niaid.nih.gov/diseases-conditions/coronaviruses
- Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005; 24: S223-S227, discussion S226 [PMID: 16378050 DOI: 10.1097/01.inf.0000188166.17324.60]
- 3 Bell DM: World Health Organization Working Group on International and Community Transmission of SARS. Public health interventions and SARS spread, 2003. Emerg Infect Dis 2004; 10: 1900-1906 [PMID: 15550198 DOI: 10.3201/eid1011.040729]
- 4 World Health Organization (WHO). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 24 July 2015. [cited 17 January 2021]. Available from: https://www.who.int/publications/m/item/summaryof-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003
- World Health Organization (WHO). MERS situation update | October 2021. October 2021. [cited 17 December 2021]. 5 Available from: https://applications.emro.who.int/docs/WHOEMCSR471E-eng.pdf?ua=1
- 6 Baharoon S, Memish ZA. MERS-CoV as an emerging respiratory illness: A review of prevention methods. Travel Med Infect Dis 2019; 101520 [PMID: 31730910 DOI: 10.1016/j.tmaid.2019.101520]
- 7 Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet 2020; 395: 1063-1077 [PMID: 32145185 DOI: 10.1016/S0140-6736(19)33221-0]
- OECD/KDI. Understanding the Drivers of Trust in Government Institutions in Korea, OECD Publishing, Paris, 2018 8
- Wu Z, McGoogan JM, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242 [PMID: 32091533 DOI: 10.1001/jama.2020.2648]
- 10 WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341 [PMID: 32876694 DOI: 10.1001/jama.2020.17023]
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, 11 Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020; 383: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]
- 12 Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854-887 [PMID: 32222812 DOI: 10.1007/s00134-020-06022-5]
- 13 Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, Gopalakrishna G, Chew SK, Tan CC, Samore MH, Fisman D, Murray M. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003; 300: 1966-1970 [PMID: 12766207 DOI: 10.1126/science.1086616]
- 14 Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis 2020; 20: e102-e107 [PMID: 32145768 DOI: 10.1016/S1473-3099(20)30129-8]
- 15 World Health Organization (WHO). Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2003. [cited 14 May 2020]. Available from: https://www.who.int/csr/sars/WHOconsensus.pdf?ua=1
- Chen J, Lu H, Melino G, Boccia S, Piacentini M, Ricciardi W, Wang Y, Shi Y, Zhu T. COVID-19 infection: the China and 16 Italy perspectives. Cell Death Dis 2020; 11: 438 [PMID: 32513951 DOI: 10.1038/s41419-020-2603-0]
- Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? J R Soc Med 2003; 96: 374-378 [PMID: 17 12893851 DOI: 10.1258/jrsm.96.8.374]
- Chan SM, Chiu FK, Lam CW, Leung PY, Conwell Y. Elderly suicide and the 2003 SARS epidemic in Hong Kong. Int J Geriatr Psychiatry 2006; 21: 113-118 [PMID: 16416469 DOI: 10.1002/gps.1432]
- 19 Wu P, Fang Y, Guan Z, Fan B, Kong J, Yao Z, Liu X, Fuller CJ, Susser E, Lu J, Hoven CW. The psychological impact of the SARS epidemic on hospital employees in China: exposure, risk perception, and altruistic acceptance of risk. Can J



Psychiatry 2009; 54: 302-311 [PMID: 19497162 DOI: 10.1177/070674370905400504]

- 20 Kwek SK, Chew WM, Ong KC, Ng AW, Lee LS, Kaw G, Leow MK. Quality of life and psychological status in survivors of severe acute respiratory syndrome at 3 mo postdischarge. J Psychosom Res 2006; 60: 513-519 [PMID: 16650592 DOI: 10.1016/j.jpsychores.2005.08.020
- 21 Lee TM, Chi I, Chung LW, Chou KL. Ageing and psychological response during the post-SARS period. Aging Ment Health 2006; 10: 303-311 [PMID: 16777659 DOI: 10.1080/13607860600638545]
- Gardner PJ, Moallef P. Psychological impact on SARS survivors: Critical review of the English language literature. Can 22 Psychol 2015; 56: 123 [DOI: 10.1037/a0037973]
- Jeong H, Yim HW, Song YJ, Ki M, Min JA, Cho J, Chae JH. Mental health status of people isolated due to Middle East 23 Respiratory Syndrome. Epidemiol Health 2016; 38: e2016048 [PMID: 28196409 DOI: 10.4178/epih.e2016048]
- 24 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135 [PMID: 25524443 DOI: 10.1186/1471-2288-14-135]
- 25 Chau SWH, Wong OWH, Ramakrishnan R, Chan SSM, Wong EKY, Li PYT, Raymont V, Elliot K, Rathod S, Delanerolle G, Phiri P. History for some or lesson for all? BMC Public Health 2021; 21: 670 [PMID: 33827499 DOI: 10.1186/s12889-021-10701-3]
- Phiri P, Ramakrishnan R, Rathod S, Elliot K, Thayanandan T, Sandle N, Haque N, Chau SW, Wong OW, Chan SS, Wong 26 EK, Raymont V, Au-Yeung SK, Kingdon D, Delanerolle G. An evaluation of the mental health impact of SARS-CoV-2 on patients, general public and healthcare professionals: A systematic review and meta-analysis. EClinicalMedicine 2021; 34: 100806 [PMID: 33842872 DOI: 10.1016/j.eclinm.2021.100806]
- Dye TD, Alcantara L, Siddiqi S, Barbosu M, Sharma S, Panko T, Pressman E. Risk of COVID-19-related bullying, 27 harassment and stigma among healthcare workers: an analytical cross-sectional global study. BMJ Open 2020; 10: e046620 [PMID: 33380488 DOI: 10.1136/bmjopen-2020-046620]
- 28 Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 611-627 [PMID: 32437679 DOI: 10.1016/S2215-0366(20)30203-0
- 29 Khan KS, Mamun MA, Griffiths MD, Ullah I. The Mental Health Impact of the COVID-19 Pandemic Across Different Cohorts. Int J Ment Health Addict 2020; 1-7 [PMID: 32837440 DOI: 10.1007/s11469-020-00367-0]
- 30 McIntyre RS, Lee Y. Projected increases in suicide in Canada as a consequence of COVID-19. Psychiatry Res 2020; 290: 113104 [PMID: 32460184 DOI: 10.1016/j.psychres.2020.113104]
- Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in 31 China: a web-based cross-sectional survey. Psychiatry Res 2020; 288: 112954 [PMID: 32325383 DOI: 10.1016/j.psychres.2020.112954]
- Greenberg N, Weston D, Hall C, Caulfield T, Williamson V, Fong K. Mental health of staff working in intensive care 32 during Covid-19. Occup Med (Lond) 2021; 71: 62-67 [PMID: 33434920 DOI: 10.1093/occmed/kgaa220]
- 33 Maunder RG. Was SARS a mental health catastrophe? Gen Hosp Psychiatry 2009; 31: 316-317 [PMID: 19555790 DOI: 10.1016/j.genhosppsych.2009.04.004]
- 34 Aldridge RW, Lewer D, Katikireddi SV, Mathur R, Pathak N, Burns R, Fragaszy EB, Johnson AM, Devakumar D, Abubakar I, Hayward A. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res 2020; 5: 88 [PMID: 32613083 DOI: 10.12688/wellcomeopenres.15922.2]
- 35 Clouston SAP, Natale G, Link BG. Socioeconomic inequalities in the spread of coronavirus-19 in the United States: A examination of the emergence of social inequalities. Soc Sci Med 2021; 268: 113554 [PMID: 33308911 DOI: 10.1016/j.socscimed.2020.113554]
- 36 Shin J, Park HY, Kim JL, Lee JJ, Lee H, Lee SH, Shin HS. Psychiatric morbidity of survivors one year after the outbreak of Middle East respiratory syndrome in Korea, 2015. J Korean Neuropsy Assoc 2019; 58: 245-251
- 37 Um DH, Kim JS, Lee HW, Lee SH. Psychological effects on medical doctors from the Middle East Respiratory Syndrome (MERS) outbreak: A comparison of whether they worked at the MERS occurred hospital or not, and whether they participated in MERS diagnosis and treatment. J Korean Neuropsy Assoc 2017; 56: 28-34
- 38 Abolfotouh MA, AlQarni AA, Al-Ghamdi SM, Salam M, Al-Assiri MH, Balkhy HH. An assessment of the level of concern among hospital-based health-care workers regarding MERS outbreaks in Saudi Arabia. BMC Infect Dis 2017; 17: 4 [PMID: 28049440 DOI: 10.1186/s12879-016-2096-8]
- Jung H, Jung SY, Lee MH, Kim MS. Assessing the Presence of Post-Traumatic Stress and Turnover Intention Among 39 Nurses Post-Middle East Respiratory Syndrome Outbreak: The Importance of Supervisor Support. Workplace Health Saf 2020; **68**: 337-345 [PMID: 32146875 DOI: 10.1177/2165079919897693]
- Ahn SH, Kim JL, Kim JR, Lee SH, Yim HW, Jeong H, Chae JH, Park HY, Lee JJ, Lee H. Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period. J Psychiatr Res 2021; 137: 1-6 [PMID: 33631632 DOI: 10.1016/j.jpsychires.2021.02.029]
- 41 Lee SH, Shin HS, Park HY, Kim JL, Lee JJ, Lee H, Won SD, Han W. Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry Investig 2019; 16: 59-64 [PMID: 30605995 DOI: 10.30773/pi.2018.10.22.3]
- Kim Y, Seo E, Seo Y, Dee V, Hong E. Effects of Middle East Respiratory Syndrome Coronavirus on post-traumatic stress 42 disorder and burnout among registered nurses in South Korea. Int J Healthc 2018; 4: 27-33
- Oh N, Hong N, Ryu DH, Bae SG, Kam S, Kim KY. Exploring Nursing Intention, Stress, and Professionalism in Response 43 to Infectious Disease Emergencies: The Experience of Local Public Hospital Nurses During the 2015 MERS Outbreak in South Korea. Asian Nurs Res (Korean Soc Nurs Sci) 2017; 11: 230-236 [PMID: 28991605 DOI: 10.1016/j.anr.2017.08.005]
- 44 Seo YE, Kim HC, Yoo SY, Lee KU, Lee HW, Lee SH. Factors Associated with Burnout among Healthcare Workers during an Outbreak of MERS. Psychiatry Investig 2020; 17: 674-680 [PMID: 32631034 DOI: 10.30773/pi.2020.0056]
- 45 Son H, Lee WJ, Kim HS, Lee KS, You M. Hospital workers' psychological resilience after the 2015 Middle East



respiratory syndrome outbreak. Soc Behav Per Int J 2019; 47: 1-3

- 46 Park JS, Lee EH, Park NR, Choi YH. Mental Health of Nurses Working at a Government-designated Hospital During a MERS-CoV Outbreak: A Cross-sectional Study. Arch Psychiatr Nurs 2018; 32: 2-6 [PMID: 29413067 DOI: 10.1016/j.apnu.2017.09.006
- 47 Al-Rabiaah A, Temsah MH, Al-Eyadhy AA, Hasan GM, Al-Zamil F, Al-Subaie S, Alsohime F, Jamal A, Alhaboob A, Al-Saadi B, Somily AM. Middle East Respiratory Syndrome-Corona Virus (MERS-CoV) associated stress among medical students at a university teaching hospital in Saudi Arabia. J Infect Public Health 2020; 13: 687-691 [PMID: 32001194 DOI: 10.1016/j.jiph.2020.01.005
- 48 Park HY, Park WB, Lee SH, Kim JL, Lee JJ, Lee H, Shin HS. Posttraumatic stress disorder and depression of survivors 12 mo after the outbreak of Middle East respiratory syndrome in South Korea. BMC Public Health 2020; 20: 605 [PMID: 32410603 DOI: 10.1186/s12889-020-08726-11
- Cho AJ, Lee HS, Lee YK, Jeon HJ, Park HC, Jeong DW, Kim YG, Lee SH, Lee CH, Yoo KD, Wong AK. Post-traumatic 49 stress symptoms in hemodialysis patients with MERS-CoV exposure. Biopsychosoc Med 2020; 14: 9 [PMID: 32308734 DOI: 10.1186/s13030-020-00181-z]
- Kim HC, Yoo SY, Lee BH, Lee SH, Shin HS. Psychiatric Findings in Suspected and Confirmed Middle East Respiratory 50 Syndrome Patients Quarantined in Hospital: A Retrospective Chart Analysis. Psychiatry Investig 2018; 15: 355-360 [PMID: 29593206 DOI: 10.30773/pi.2017.10.25.1]
- 51 Lee SM, Kang WS, Cho AR, Kim T, Park JK. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. Compr Psychiatry 2018; 87: 123-127 [PMID: 30343247 DOI: 10.1016/j.comppsych.2018.10.003]
- 52 Kim JS, Choi JS. Factors Influencing Emergency Nurses' Burnout During an Outbreak of Middle East Respiratory Syndrome Coronavirus in Korea. Asian Nurs Res (Korean Soc Nurs Sci) 2016; 10: 295-299 [PMID: 28057317 DOI: 10.1016/j.anr.2016.10.002
- 53 Bukhari EE, Temsah MH, Aleyadhy AA, Alrabiaa AA, Alhboob AA, Jamal AA, Binsaeed AA. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak perceptions of risk and stress evaluation in nurses. J Infect Dev Ctries 2016; 10: 845-850 [PMID: 27580330 DOI: 10.3855/jidc.6925]
- 54 Mollers M, Jonges M, Pas SD, van der Eijk AA, Dirksen K, Jansen C, Gelinck LB, Leyten EM, Thurkow I, Groeneveld PH, van Gageldonk-Lafeber AB, Koopmans MP, Timen A; MERS-CoV Outbreak Investigation Team of the Netherlands. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus-Infected Returning Travelers, the Netherlands, 2014. Emerg Infect Dis 2015; 21: 1667-1669 [PMID: 26291986 DOI: 10.3201/eid2109.150560]
- 55 Fang Y, Zhe D, Shuran LI. Survey on mental status of subjects recovered from SARS. Zhongguo Xinli Jiankang Zazhi 2004
- 56 Liang CC. Stress reaction, emotional effects and posttraumatic stress disorder in severe acute respiratory syndrome patients: a follow-up study. Unpublished Thesis. National Taipei University of Nursing and Health Sciences, Taiwan, 2004
- 57 Dang WM, Huang YQ, Liu ZR, Li S. Analysis of anxiety and depression symptoms and related factors in three universities during SARS epidemic in Beijing. Zhongguo Xingwei Yixue Zazhi 2004; 13: 437-439
- 58 Yip KW. Ten-year Follow-up Study on Psychiatric Morbidity in Survivors of Severe Acute Respiratory Syndrome. Unpublished Thesis. United Chrisian Hospital, Hong Kong 2015
- 59 Cheng SK, Wong CW, Tsang J, Wong KC. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS). Psychol Med 2004; 34: 1187-1195 [PMID: 15697045 DOI: 10.1017/s0033291704002272]
- Wu KK, Chan SK, Ma TM. Posttraumatic stress after SARS. Emerg Infect Dis 2005; 11: 1297-1300 [PMID: 16102324 60 DOI: 10.3201/eid1108.041083]
- Mak IW, Chu CM, Pan PC, Yiu MG, Chan VL. Long-term psychiatric morbidities among SARS survivors. Gen Hosp Psychiatry 2009; 31: 318-326 [PMID: 19555791 DOI: 10.1016/j.genhosppsych.2009.03.001]
- Lee AM, Wong JG, McAlonan GM, Cheung V, Cheung C, Sham PC, Chu CM, Wong PC, Tsang KW, Chua SE. Stress and 62 psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry 2007; 52: 233-240 [PMID: 17500304 DOI: 10.1177/070674370705200405]
- 63 Hong X, Currier GW, Zhao X, Jiang Y, Zhou W, Wei J. Posttraumatic stress disorder in convalescent severe acute respiratory syndrome patients: a 4-year follow-up study. Gen Hosp Psychiatry 2009; 31: 546-554 [PMID: 19892213 DOI: 10.1016/j.genhosppsych.2009.06.008]
- Wang J. Psychological conditions of patients with fever during the epidemic of infectious atypical pneumonia. Chin J Clin 64 Rehabil 2003; 7: 4162
- Hu HY, Li M, Zhou L, Zhang H, Wang T. Effect of coping style and social support on the psychologic status in patients 65 with severe acute respiratory syndrome. Chin J Clin Rehabil 2004; 8: 1022-1023
- 66 Chen R, Chou KR, Huang YJ, Wang TS, Liu SY, Ho LY. Effects of a SARS prevention programme in Taiwan on nursing staff's anxiety, depression and sleep quality: a longitudinal survey. Int J Nurs Stud 2006; 43: 215-225 [PMID: 15927185 DOI: 10.1016/j.ijnurstu.2005.03.006]
- Ko CH, Yen CF, Yen JY, Yang MJ. Psychosocial impact among the public of the severe acute respiratory syndrome 67 epidemic in Taiwan. Psychiatry Clin Neurosci 2006; 60: 397-403 [PMID: 16884438 DOI: 10.1111/j.1440-1819.2006.01522.x]
- Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis 2004; 10: 1206-1212 [PMID: 15324539 DOI: 10.3201/eid1007.030703]
- Liu X, Kakade M, Fuller CJ, Fan B, Fang Y, Kong J, Guan Z, Wu P. Depression after exposure to stressful events: lessons 69 learned from the severe acute respiratory syndrome epidemic. Compr Psychiatry 2012; 53: 15-23 [PMID: 21489421 DOI: 10.1016/j.comppsych.2011.02.003]
- 70 Su TP, Lien TC, Yang CY, Su YL, Wang JH, Tsai SL, Yin JC. Prevalence of psychiatric morbidity and psychological adaptation of the nurses in a structured SARS caring unit during outbreak: a prospective and periodic assessment study in Taiwan. J Psychiatr Res 2007; 41: 119-130 [PMID: 16460760 DOI: 10.1016/j.jpsychires.2005.12.006]
- Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, So WY, Fong SY, Lam SP. Mental morbidities and chronic 71



fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009; 169: 2142-2147 [PMID: 20008700 DOI: 10.1001/archinternmed.2009.384]

- 72 Shi C, Yu X, Hong N, Chan RC, Chen Y, He Y. Emotional, memory and daily function among health care worker survivors with SARS. Chin Ment Health J 2011; 25: 660-665
- 73 Huang W, Hua Q, Wu H, Xu WY, Tian JH, Chen H, Yang FC, Yang S, Liu CH, Li XW, Ji XM, Zhang J. [A study on the differences of emotion and depression between patients as doctor/nurse and others occupation with severe acute respiratory syndrome]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 23-26 [PMID: 15061942]
- 74 Yu HY, Ho SC, So KF, Lo YL. The psychological burden experienced by Hong Kong midlife women during the SARS epidemic. Stress Health 2005; 21: 177-184
- Chang WC, Sivam RW. Constant vigilance: Heritage values and defensive pessimism in coping with severe acute 75 respiratory syndrome in Singapore. Asian J Soc Psychol 2004; 7: 35-53
- Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-76 SARS syndrome; a case-controlled study. BMC Neurol 2011; 11: 37 [PMID: 21435231 DOI: 10.1186/1471-2377-11-37]
- 77 Sun Y, Xu Y, Zhang Kr YH. Follow-up study on PTSD of SARS patients. Chin J Health Educ 2005; 8: 572-575
- 78 Lau JT, Yang X, Tsui HY, Pang E, Wing YK. Positive mental health-related impacts of the SARS epidemic on the general public in Hong Kong and their associations with other negative impacts. J Infect 2006; 53: 114-124 [PMID: 16343636 DOI: 10.1016/j.jinf.2005.10.019]
- 79 Reynolds DL, Garay JR, Deamond SL, Moran MK, Gold W, Styra R. Understanding, compliance and psychological impact of the SARS quarantine experience. *Epidemiol Infect* 2008; **136**: 997-1007 [PMID: 17662167 DOI: 10.1017/S0950268807009156
- Lancee WJ, Maunder RG, Goldbloom DS; Coauthors for the Impact of SARS Study. Prevalence of psychiatric disorders 80 among Toronto hospital workers one to two years after the SARS outbreak. Psychiatr Serv 2008; 59: 91-95 [PMID: 18182545 DOI: 10.1176/ps.2008.59.1.91]
- 81 Lin CY, Peng YC, Wu YH, Chang J, Chan CH, Yang DY. The psychological effect of severe acute respiratory syndrome on emergency department staff. Emerg Med J 2007; 24: 12-17 [PMID: 17183035 DOI: 10.1136/emj.2006.035089]
- Gao H, Hui W, Lan X, Wei J, Hu YL, Li R, Zhang ZQ, Yuan ST, Jiao ZS. A follow-up study of post-traumatic stress 82 disorder of SARS patients after discharge. Chin J Rehabil Med 2006; 21: 1003-1004
- 83 Xu Y, Zhang K, Xue Y. A study on post-traumatic stress reaction of hospital staffs worked in the ward of SARS. Huli Yanjiu 2004; 2: 179-181
- Wong S. Psychological reaction of healthcare workers in the outbreak and aftermath of severe acute respiratory syndrome. 84 Unpublished Thesis. The University of Hong Kong, Hong Kong. 2004. [cited 17 January 2021]. Available from: https://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0029-1812201200003583
- Sin SS, Huak CY. Psychological impact of the SARS outbreak on a Singaporean rehabilitation department. Int J Ther 85 Rehabil 2004; 11: 417-424
- Chen CS, Wu HY, Yang P, Yen CF. Psychological distress of nurses in Taiwan who worked during the outbreak of SARS. 86 Psychiatr Serv 2005; 56: 76-79 [PMID: 15637196 DOI: 10.1176/appi.ps.56.1.76]
- 87 Tham KY, Tan YH, Loh OH, Tan WL, Ong MK, Tang HK. Psychiatric morbidity among emergency department doctors and nurses after the SARS outbreak. Ann Acad Med Singap 2004; 33: S78-S79 [PMID: 15651222]
- 88 Maunder RG, Lancee WJ, Balderson KE, Bennett JP, Borgundvaag B, Evans S, Fernandes CM, Goldbloom DS, Gupta M, Hunter JJ, McGillis Hall L, Nagle LM, Pain C, Peczeniuk SS, Raymond G, Read N, Rourke SB, Steinberg RJ, Stewart TE, VanDeVelde-Coke S, Veldhorst GG, Wasylenki DA. Long-term psychological and occupational effects of providing hospital healthcare during SARS outbreak. Emerg Infect Dis 2006; 12: 1924-1932 [PMID: 17326946 DOI: 10.3201/eid1212.060584]
- 89 Mak IW, Chu CM, Pan PC, Yiu MG, Ho SC, Chan VL. Risk factors for chronic post-traumatic stress disorder (PTSD) in SARS survivors. Gen Hosp Psychiatry 2010; 32: 590-598 [PMID: 21112450 DOI: 10.1016/j.genhosppsych.2010.07.007]
- McAlonan GM, Lee AM, Cheung V, Cheung C, Tsang KW, Sham PC, Chua SE, Wong JG. Immediate and sustained 90 psychological impact of an emerging infectious disease outbreak on health care workers. Can J Psychiatry 2007; 52: 241-247 [PMID: 17500305 DOI: 10.1177/070674370705200406]





# Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

